

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Comparison of demographic, clinical and laboratory characteristics between first and second COVID-19 waves in a secondary care hospital in Qatar: A retrospective study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-061610
Article Type:	Original research
Date Submitted by the Author:	01-Feb-2022
Complete List of Authors:	<p>NAUSHAD, VAMANJORE; Hamad Medical Corporation, Medicine; Qatar University College of Medicine PURAYIL, NISHAN; Hamad Medical Corporation, Medicine; Qatar University College of Medicine CHANDRA, PREM; Hamad Medical Corporation, MEDICAL RESEARCH CENTER Saeed, Abazar Ahmad M; Hamad Medical Corporation, Medicine Radhakrishnan, Pradeep; Hamad Medical Corporation, Medicine VARIKKODAN, IRFAN; Hamad Medical Corporation, Medicine Mathew, Joe V; Hamad Medical Corporation, Medicine; Qatar University College of Medicine Sirajudeen, Jaseem; Hamad Medical Corporation, Medicine; Qatar University College of Medicine Hammamy, Riyadh A; Hamad Medical Corporation, Medicine Badi, Ahmad M; Hamad Medical Corporation, Medicine; Qatar University College of Medicine Suliman, Asir M; Hamad Medical Corporation, Medicine Badawi, Mohamed N; Hamad Medical Corporation, Department of Infectious Diseases Arya, Saket; Hamad Medical Corporation, Ophthalmology AlMotawa, Maryam; Qatar University College of Medicine Al-Baker, Aisha; Qatar University College of Medicine Alatom, Rania; Qatar University College of Medicine Kartha, Anand; Hamad Medical Corporation, Medicine; Weill Cornell Medicine - Qatar</p>
Keywords:	COVID-19, EPIDEMIOLOGY, INFECTIOUS DISEASES, Epidemiology < INFECTIOUS DISEASES

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Title

Comparison of demographic, clinical and laboratory characteristics between first and second COVID-19 waves in a secondary care hospital in Qatar: A retrospective study

Key words

COVID-19 infection, Coronavirus, SARS-CoV-2, Pandemic, First wave, Second wave

For peer review only

Authors and affiliations

Vamanjore A Naushad^{1, 5}

Nishan K Purayil^{1, 5} Email-nishankp@live.com

Prem Chandra² Email-pchandra@hamad.qa

Abazar Ahmad M Saeed¹ Email-asaeed5@hamad.qa

Pradeep Radhakrishnan¹ Email-pradhakrishnan@hamad.qa

Irfan Varikkodan¹ Email-ivarikkodan@hamad.qa

Joe V Mathew^{1, 5} Email-jmathew13@hamad.qa

Jaseem Sirajudeen^{1, 5} Email-jsirajudeen@hamad.qa

Riyadh A Hammamy¹ Email-rhammamy@hamad.qa

Ahmad M Badi^{1, 5} Email-abadi@hamad.qa

Aasir M Suliman¹ Email-asuliman4@hamad.qa

Mohamed N Badawi³ Email-mmohamed21@hamad.qa

Saket Arya⁴ Email-sarya@hamad.qa

Maryam AlMotawa⁵ Email-malmotawa@hamad.qa

Aisha Al-Baker⁵ Email-aalbaker4@hamad.qa

Rania Alatom⁵ Email-Ra1601687@qu.edu.qa

Anand B Kartha^{1, 6} Email-akartha@hamad.qa

1
2
3
4
5
6
7
8
9 1- Department of Medicine

10
11 Hamad Medical Corporation

12
13 2- Medical Research Center

14
15 Hamad Medical Corporation

16
17 3- Department of Infectious Diseases

18
19 Hamad Medical Corporation

20
21 4- Department of Ophthalmology

22
23 Hamad Medical Corporation

24
25 5- College of Medicine- Qatar University

26
27 6-Weill Cornell Medicine-Qatar

28
29
30
31
32
33
34
35
36
37
38 **Corresponding Author**

39
40 V.A.Naushad

41
42 General Internal Medicine Department

43
44 Hamad General Hospital

45
46 Hamad Medical Corporation

47
48 Doha, Qatar

49
50 Email-nousha87@hotmail.com

51
52 Email-vnaushad@hamad.qa

Abstract

Objective: To compare the patient profiles in Qatar during the first and second waves of the COVID-19 pandemic. **Setting:** A retrospective observational study was conducted comparing the demographic, clinical, and laboratory characteristics of patients with COVID-19 infection admitted to a secondary care hospital in Qatar, during the first and second waves of the pandemic.

Participants: 1039 patients from the first wave and 991 from the second wave who had pneumonia on chest X-ray and had a laboratory-confirmed SARS-CoV-2 infection by a real-time PCR test of a nasopharyngeal swab specimen were included. The study excluded patients with a normal chest X-ray and those who had a positive COVID-19 antigen test but a negative PCR test. **Outcome:** Length of stay, need for mechanical ventilation, final disposition and mortality were the key outcomes studied **Results:** Upper respiratory symptoms (18.5 % vs. 36.1 %, $p < 0.001$), cough (79.2% vs.87%, $p < 0.001$) and dyspnea (27.5% vs. 38% $p < 0.001$) were more common in the second wave. Second wave patients had significantly higher respiratory rate, lower peripheral oxygen saturation, needed more supplemental oxygen and had higher incidence of pulmonary embolism. More patients received hydroxychloroquine and antibiotics during the first wave and more received steroids, antivirals and interleukin-1 antagonist during the second wave. The second wave had a shorter length of stay (14.58 ± 7.75 vs. 12.61 ± 6.16), $p < 0.001$) and more patients were discharged home (22% vs. 10% $p < 0.001$).

Conclusions: Patients who presented during the second wave of Covid-19 pandemic appeared to be more ill clinically and based on their laboratory

1
2
3 parameters. However, they required shorter hospitalization and were more likely
4 to be discharged home. This could represent greater expertise in handling such
5 patients that was acquired during the first wave as well as use of more
6 appropriate and combination therapies during the second wave.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Introduction

Coronavirus disease 2019 (COVID-19), first identified in the Wuhan province of China, was declared a global pandemic by the World health organization (WHO) on March 11th, 2020 [1]. To date, it has affected 311,207,461, with more than 5 million deaths worldwide. In Qatar, COVID-19 infection has affected 278,698 individuals with 621 deaths [2]. In Qatar, the first wave began in March 2020 and peaked in May 2020 whereas second wave began in February 2020 and reached its peak in April 2021.

During both pandemic waves, Ras Laffan Hospital, a secondary care hospital, was one of the COVID-19 designated hospitals under Hamad Medical Corporation (HMC). If patients met the admission criteria, they were transferred to Ras Laffan Hospital from non-COVID hospitals and tertiary care COVID facilities. During the first and second waves, respectively, 3650 and 4050 patients with a confirmed SARS-CoV-2 infection were hospitalized and treated at the Ras Laffan hospital.

From the time it was originally discovered in Wuhan, the disease profile, epidemiology, and treatment guidelines for COVID-19 infection had evolved continuously. On the basis of the most recent scientific findings, WHO released and updated diagnostic and treatment guidelines, as well as quarantine guidelines, on a regular basis. Countries around the world revised their management and quarantine standards on a regular basis based on this and locally available data.

1
2
3 In the Middle East region, there is a dearth of published data comparing
4 epidemiology and outcomes of serial waves of the COVID-19 epidemic. As a
5 result, we chose to investigate and compare these in both waves better
6 understand and manage future events.
7
8
9
10

11 **Objective**

12
13 The goal of this study was to examine admission characteristics and outcomes in
14 COVID-19-infected hospitalized patients during the first and second waves of the
15 pandemic.
16
17
18
19
20
21
22

23 **Methods**

24 **Study type and setting**

25
26 A retrospective observational study was conducted at Ras Laffan hospital, Hamad
27 Medical Corporation, Qatar. This hospital was one of the COVID-19 designated
28 hospitals under HMC. The study was conducted from June 2021 to September
29 2021.
30
31
32
33
34
35
36
37

38 **Study participants**

39
40 Patients admitted between 1st to 30th of May 2020 in the first wave and those
41 admitted between 1st and 15th of March 2021 during the second wave were
42 included in the study. The patients were included if they had pneumonia on chest
43 X-ray and had a laboratory-confirmed SARS-CoV-2 infection by a real-time PCR
44 test of a nasopharyngeal swab specimen. The study excluded patients with a
45 normal chest X-ray and those who had a positive COVID-19 antigen test but a
46 negative PCR test.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Patient and public involvement

No patient involved

Data collection

Using the patients' health care numbers, files from the clinical information system were reviewed. Data was collected on demographics, admission symptoms, co-morbidities, length of stay, laboratory and radiographic results, oxygen requirements, treatment details, complications, and outcomes.

Outcome of the study

The requirement for mechanical ventilation, length of stay, final disposition and mortality were the key outcomes studied along with their clinical and laboratory characteristics.

Statistical analysis

The data were analyzed using IBM SPSS Statistics version 27 (Armonk, NY: IBM Corp) and the level of significance was set at a P value < 0.05. Descriptive statistics were used to summarize demographic, anthropometric, clinical, laboratory, radiological characteristics, and related follow-up outcome measures of these patients. Continuous variables with normal distribution were presented as mean and standard deviation (SD), whereas median and interquartile range (IQR) was used in case of skewed/non-normal data. Categorical variables were presented as frequencies and proportions. The Shapiro-Wilk test was used to test for normality of the data distribution. The statistical P-value for outcomes measured quantitatively and differences between the two independent groups

(first and second COVID-19 waves) were compared using unpaired t or Mann Whitney U tests as appropriate depending on the normality of the data distribution. Associations between two or more qualitative or categorical variables across two independent groups were compared using Pearson Chi-square or Fisher exact test as applicable. Box plots were constructed to depict distribution of age, duration of symptoms, BMI, vital signs, and various parameters related to laboratory profiles across both groups first and second COVID-19 waves.

Results

Baseline demographic characteristics

During the first and second waves, respectively, 3650 and 4050 patients with a confirmed SARS-CoV-2 infection were hospitalized. The study included 1039 patients from the first wave and 991 participants from the second wave. During both waves, the average age of the subjects was similar [44.9 ± 9.9 vs. 44.34 ± 9.56]. In both waves, the proportion of patients among various age groups was comparable, with the majority of patients being between the ages of 36 and 50. (52.9 % vs. 54.0 %). Males made up 95.2 % of the first wave and 88.5 % of the second wave patients (Table 1).

Clinical characteristics on admission

In the first wave patients had longer duration of symptoms prior to admission compared to second wave (4.88 ± 2.91 vs. 4.57 ± 2.50 , $p 0.010$). Upper respiratory symptoms (36.1% vs. 18.5%, $p < 0.001$), cough (87% vs. 79.2%, $p < 0.001$), and shortness of breath (38% vs. 27.5%, $p < 0.001$), were significantly higher in the

1
2
3 second wave than the first. We did not find any significant difference in
4
5 gastrointestinal symptoms between the two waves.
6
7

8 Diabetes mellitus (29.5% vs. 21.9%) and hypertension (26 % vs. 26.5%) were the
9
10 most common co-morbid conditions observed in both waves; however, frequency
11
12 of diabetes mellitus was significantly higher in the first wave ($p < 0.001$)
13
14

15 The mean body mass index (BMI) was 27.95 ± 4.46 and 28.29 ± 4.83 in the first
16
17 and second waves, respectively ($p = 0.263$). Most patients had higher BMI in both
18
19 the waves, with the majority having a BMI between 25.1 to 30 (48.2% vs. 45%)
20
21 followed by more than 30 (27.1% vs. 28.5%) (Table-1). The details of distribution
22
23 of age, duration of symptoms and BMI are plotted in Figure 1 A-C.
24
25

26 27 **Vital signs and oxygen requirement**

28
29 Patients in the second wave had significantly higher respiratory rate (23 ± 6 vs.
30
31 22 ± 5 , $p < 0.001$) and significantly lower peripheral oxygen saturation (93 ± 5 vs.
32
33 94 ± 4 , $p < 0.001$) when compared to the first wave. Furthermore, during the second
34
35 wave significantly higher number of patients received supplemental oxygen on
36
37 admission (40.3% vs. 22.9 %, $p < 0.001$) and also during their stay in the hospital
38
39 (39.8% vs. 30.3%, $p < 0.001$) Table- 2 and figure 2 A-H.
40
41
42
43

44 45 **Laboratory parameters and chest X-ray findings**

46
47 The first wave had significantly higher C-reactive protein (50.54 ± 53.28 vs. 33.68
48
49 ± 44.20 , $p < 0.001$) and HbA1c values (7.37 ± 2.04 vs. 6.94 ± 1.83 , $p < 0.001$). The mean
50
51 values of white blood cell count (6.49 ± 2.41 vs. 6.27 ± 2.21 , $p = 0.031$), hemoglobin
52
53 (14.35 ± 1.37 vs. 14.16 ± 1.43 , $p = 0.003$), and platelet counts (234.99 ± 89.44 vs.
54
55
56
57
58
59
60

1
2
3 225.55 ±82.50, p 0.014) were lower in the second wave than the first. The
4
5 patients in the second wave, had considerably lower mean albumin levels than
6
7 the first wave (35.58 ±4.94 vs. 36.97 ±4.83, p<0.001). Patients in the second wave
8
9 had higher hepatic transaminases and alkaline phosphatase levels than the first
10
11 wave, although the differences were statistically insignificant. In both waves, the
12
13 majority of patients had bilateral pneumonia on chest x-ray. Table- 3 and figure 3
14
15
16 A-K.

17 18 19 **Treatment received**

20
21
22 In the first wave, the usage of amoxicillin/clavulanic acid (60.9% vs.29.3%) and
23
24 azithromycin/clarithromycin (74.1% vs. 41.9%) and usage of hydroxychloroquine
25
26 (88.5% vs. 60.3%, p<0.001) was higher.

27
28
29 A significantly higher number of patients in the second wave received steroids
30
31 (47.7% vs.17.1%, p <0.001), favipiravir (71% vs. 22.1%, p<0.001) or
32
33 lopinavir/ritonavir (63.6% vs. 35.5%, p<0.001 and anakinra (10.6% vs. 2.7%, p
34
35 <0.001).

36
37
38 Similar number of patients in both the waves received cephalosporins (74.3% vs.
39
40 70.5%, p=0.058) and prophylactic anticoagulation (97.4% vs. 99%).Table - 4.

41 42 43 **Complications/ outcome and disposition**

44
45
46 In the first and second waves, 5.3% and 6.5 %of patients, respectively, required
47
48 transfer to a higher center for further care. Among those who were transferred,
49
50 28 (2.7%) patients in the first wave and 40 (4%) in the second wave received
51
52 mechanical ventilation (p= 0.093). In the second wave, the percentage of patients
53
54
55
56
57
58
59
60

1
2
3 who developed pulmonary embolism was significantly higher (1.1 % vs. 0.03%,
4 p=0.025), furthermore, a higher proportion of mortality (0.81% (8/991) vs. 0.3%
5 (3/1030)) was recorded in the second wave, however this difference was
6 statistically insignificant (p=0.112).
7
8
9
10

11
12 The majority of patients in the first wave stayed for 15 to 30 days (50.9 % vs.
13 21.4%), while the majority of patients in the second wave stayed for 8 to 14 days
14 (64.4% vs. 25.15%), table 5. In the second wave, the average length of stay was
15 1.9 days shorter which was statistically significant (14.58 ±7.75 vs. 12.61 ±6.16, p
16 <0.001).
17
18
19
20
21
22

23
24 The majority of the patients in both the waves were transferred to quarantine
25 facilities from the hospital (84.6% vs. 71.1%). In the second wave, however, more
26 patients were discharged to their homes.
27
28
29
30

31 Discussion

32
33 To our knowledge, this is the first study in the region to compare COVID-19
34 individuals hospitalized during the first and second waves of the SARS-CoV-2
35 pandemic. Our findings show a significant variation between the two waves in
36 terms of clinical features, laboratory markers and outcomes.
37
38
39
40
41
42

43
44 There was no difference in the average age of the patients between the two
45 waves. In confirmation to our findings, a previous study by Wolfsburg et al. [3]
46 found no difference in the mean age of patients between two waves (65.9 vs.
47 65.8 years), whereas in contrast to our results a study by Iftimie et al. [4] found
48 that the patients in the second wave were significantly younger than the first
49 wave (58 years vs. 67 years). However, our study sample was much younger in
50
51
52
53
54
55
56
57
58
59
60

1
2
3 both waves [44.90 ±9.99 vs. 44.34 ±9.57] than the above two study populations.
4
5 On admission to the hospital cough, shortness of breath and upper respiratory
6
7 symptoms were more common in the second wave. The patients in the second
8
9 wave had more symptoms and were sicker as evidenced by tachypnea and
10
11 hypoxia and more patients requiring oxygen. We did not observe a significant
12
13 difference in the prevalence of gastrointestinal symptoms between both the
14
15 waves. This is in contrast to previous research [4, 5], which reported a higher
16
17 prevalence of gastrointestinal complaints in the in the second wave.
18
19

20
21 The most common co-morbidities in both waves of the research population were
22
23 diabetes mellitus and hypertension. The number of diabetes patients, on the
24
25 other hand, was much higher in the first wave. When comparing co-morbidities in
26
27 both the waves, previous research have yielded conflicting outcomes. Iftimie et al.
28
29 [4] showed no significant differences in co-morbidity between the two waves,
30
31 however Jarrett et al. [6] and Sargin et al. [7] identified a higher frequency of
32
33 chronic kidney illness in the second wave than in the first wave.
34
35

36
37 Despite the fact that the mean BMI did not alter significantly between the two
38
39 waves, the majority of our research group had a higher BMI in both, suggesting
40
41 obesity as a probable risk factor for COVID-19 infection. However this needs
42
43 further studies analyzing the correlation between obesity as a risk factor and
44
45 Covid-19 infection. Obesity was found in 30% of the whole study population in
46
47 both waves, according to a study from Switzerland [3]. Another study from the
48
49 United States [6] found that the second wave had a higher BMI than the first
50
51 wave (32.58 vs. 29.83).
52
53
54
55
56
57
58
59
60

1
2
3 The study of laboratory measurements revealed that the first wave had higher
4 mean values of CRP and HbA1c, while hypoalbuminemia was significantly higher
5 in the second wave. Furthermore levels of leukocyte and platelet count were
6 lower in second wave than the first wave. The second wave had higher mean
7 levels of hepatic transaminases. The higher HbA1c readings in the first wave are
8 unsurprising given the higher prevalence of diabetes mellitus in the first wave
9 compared to the second wave. The higher hepatic transaminases in the second
10 wave could be due to a variety of factors. One probable reason could be
11 secondary to the side effect of favipiravir, as it was used more frequently in the
12 second wave than in the first wave.
13
14
15
16
17
18
19
20
21
22
23
24

25
26 In our study population, the use of steroids was much higher in the second wave
27 [47% vs. 17%]. This is because during the early stage of the first wave scientific
28 literature regarding the benefit of steroids in COVID-19 infection was still in its
29 preliminary stage and its use was limited. The frequency of usage of steroids in
30 published data was still greater (99% [6], 76% [3]) than ours in the second wave.
31 Because the aforementioned two studies included individuals with more severe
32 disease than our research sample, the frequency of steroid administration
33 differed. In terms of prophylactic anticoagulation, practically more than 97% of
34 the patients in both waves received anticoagulation in our research group. This
35 was much greater than the 59% in the first wave and 74% in the second wave
36 reported in a research conducted in the United States [6].
37
38
39
40
41
42
43
44
45
46
47
48
49

50 The usage of hydroxychloroquine was significantly higher in the first wave,
51 whereas the use of favipiravir and anakinra was much higher in the second wave,
52 according to our findings. This is because treatment guidelines evolved and
53
54
55
56
57
58
59
60

1
2
3 modified from the first wave to the second wave based on published scientific
4 information around the world. Furthermore, use of antibiotics was significantly
5 higher in the first wave than the second wave. There are multiple reasons for this.
6
7 First, during the first wave azithromycin was more commonly used along with
8 hydroxychloroquine as a treatment for COVID-19 infection. Second, due to lack of
9 experience and expertise in managing the COVID-19 pandemic antibiotics were
10 more commonly prescribed for patients with COVID pneumonia during the first
11 wave; however during the second wave clinicians acquired adequate knowledge
12 and experience and were more confident to treat patients without antibiotics
13 unless indicated.
14
15

16
17
18 Despite the fact that patients in the second wave were sicker as evidenced by
19 more symptoms, tachypnea and hypoxia on admission and laboratory
20 parameters, the duration of hospitalization were significantly lower in the second
21 wave. In the present study the average length of stay in the second wave was
22 nearly 2 days less than in the first. This supports the findings of other research [3,
23 4, 7], which similarly found a shorter length of stay in the second wave. In
24 addition more patients were discharged home in the second wave than
25 transferred to quarantine facility. Possible explanation for this could be the
26 change in discharge/transfer criteria. Secondly, better understanding of the
27 disease course and experience of managing the first wave made the health care
28 professionals more confident in early discharge of patients in the second wave.
29
30 Finally, better home surveillance of discharged patients, development of better
31 follow up care, and community awareness and education might have also played
32 an important role.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Even while the number of patients who needed to be transferred to a higher center, those who needed mechanical ventilation, had a pulmonary embolism and those who died were all somewhat higher in the second wave than in the first, the difference was not statistically significant. Available published data from two studies, one from Switzerland [3] and another from Turkey [7] found no significant difference in the proportion of patients requiring or at risk for Intensive Care Unit (ICU) admission in both the waves. However, the percentage of patients needing ICU care in the above two studies was higher than our results in both the waves. This could be related to the fact that our study and theirs had different severity of cases and also could be due to the difference in admission criteria in our study and others. Our admission criteria included patients with pneumonia requiring less than 4 L of oxygen at the time of admission, whereas other studies included more severe cases or ICU cases. Others have reported similar results, finding no substantial change in the number of patients requiring mechanical ventilation in both waves [6, 7]. There was no significant change in mortality rates between the two waves in the present study. Previous research comparing mortality rates between the two COVID-19 pandemic waves came up with mixed results. Our findings are consistent with those of Wolfisberg et al.[3] and Sargin et al. [7], who found no difference in mortality rates between the two waves, but Iftimie et al.[4] and Jarrett et al.[6] reported lower mortality in the second wave, in contrast to our findings. Similarly, two studies from the United States found that the second wave had a reduced mortality rate [8, 9]. According to published statistics from Japan based on a public registry reported that the second wave of patients were younger, had fewer underlying co-morbidities, and had lower mortality rates [10].

1
2
3 A few studies from Europe also found lower mortality in the second wave. Chest
4 X-ray severity of pneumonia, in-hospital mortality, and CRP readings were
5 considerably greater in the first wave, according to an Italian study involving 200
6 Caucasian males over 50 years. They also discovered that the first wave had more
7 patients who required mechanical ventilation [11]. Another study from Spain
8 found that the second wave had younger patients, a shorter duration of stay in
9 the hospital, fewer invasive mechanical ventilation, and decreased mortality [4].
10
11
12
13
14
15
16
17
18

19 **Limitations**

20
21
22 There were certain limitations to our research. To begin with, some data on co-
23 morbidity and symptoms may have been overlooked due to the retrospective
24 nature of the study. Second, there might have been selection bias because our
25 research population was mostly male patients as most female COVID-19 patients
26 were admitted to other COVID designated hospitals. As a result, the number of
27 female patients in our study may have been underestimated. Third, because our
28 research sample included only mild to moderate Covid-19 infections, the findings
29 may not be generalized to severe COVID -19 infections. Finally, the relationship
30 between risk variables and outcomes was not examined as it was not the primary
31 goal of our study.
32
33
34
35
36
37
38
39
40
41
42
43

44 **Conclusions**

45
46
47 Patients in the second wave were more symptomatic and unwell than those in the
48 first wave, but they stayed in the hospital for a shorter time and were more likely
49 to be discharged home, according to our data. The most prevalent symptoms in
50 both waves were cough and shortness of breath, although they were much
51
52
53
54
55
56
57
58
59
60

1
2
3 greater in the second wave. Diabetes mellitus and raised CRP levels were more
4 common in the first wave, but hypoalbuminemia was more prevalent in the
5 second wave. In the first wave, antibiotics and hydroxychloroquine were more
6 commonly utilized, but in the second wave, steroids, antivirals, and interleukin-1
7 antagonists were more commonly employed. The first wave's experience and
8 lessons acquired by health care professionals, as well as a collaborative team
9 effort involving numerous government agencies and community awareness and
10 engagement, have helped us to manage the second wave more effectively.
11
12
13
14
15
16
17
18
19
20

21 **Strengths**

- 22 ● First study in the region to compare patient characteristics between the two
23 waves
- 24 ● All patient variables were compared, including demographics, clinical
25 complaints, vital signs, laboratory indicators, and outcomes.
26
27
28
29
30
31
32
33

34 **Limitations**

- 35 ● The relationship between risk factors and outcomes was not investigated.
36
37
38
39
40
41 ● Patients with severe COVID-19 were not included
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Author's contribution

VN- Study design, data collection, analysis, manuscript writing, editing

NP- Study design, data collection, analysis, manuscript writing, editing

PC- Study design, data analysis, editing

AS- Data collection, analysis

PR- Data collection, analysis

IV- Study design, editing

JM- Analysis, manuscript writing

JS- Data collection, literature review

RH- Data collection, manuscript writing

AB- Data collection, manuscript writing

AA- Data collection, editing

MB- Data analysis, manuscript writing

SA- Data collection, manuscript writing

MA- Data collection, editing

AA- Data collection, literature review

RA- Data collection, literature review

AK- Data analysis, manuscript writing, editing

Acknowledgement

Nil

Competing interests' statement

The authors declare that they have no competing interest involved

Funding

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors

Data sharing statement

No additional data available

Ethical approval

The study was approved by the Institutional Review Board of medical research center, Hamad, Medical Corporation (Approval no-MRC-01-21-312).

References

1. <https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020>
2. <https://covid19.moph.gov.qa/EN/Pages/default.aspx>
3. Wolfisberg S, Gregoriano C, Struja T, et al. Comparison of characteristics, predictors and outcomes between the first and second COVID-19 waves in a tertiary care centre in Switzerland: an observational analysis. *Swiss Med Wkly*. 2021;151:w20569. Published 2021 Aug 10. doi:10.4414/smw.2021.20569
4. Iftimie S, López-Azcona AF, Vallverdú I, et al. First and second waves of coronavirus disease-19: A comparative study in hospitalized patients in Reus, Spain. *PLoS One*. 2021;16(3):e0248029. Published 2021 Mar 31. doi:10.1371/journal.pone.0248029
5. Jalali SF, Ghassemzadeh M, Mouodi S, et al. Epidemiologic comparison of the first and second waves of coronavirus disease in Babol, North of Iran. *Caspian J Intern Med*. 2020;11(Suppl 1):544-550. doi:10.22088/cjim.11.0.544
6. Jarrett SA, Lo KB, Shah S, et al. Comparison of Patient Clinical characteristics and Outcomes Between Different COVID-19 Peak Periods: A Single Center Retrospective Propensity Matched Analysis. *Cureus*. 2021;13(6):e15777. Published 2021 Jun 20. doi:10.7759/cureus.15777
7. Sargin Altunok E, Satici C, Dinc V, et al. Comparison of demographic and clinical characteristics of hospitalized COVID-19 patients with severe/critical illness in the first wave versus the second wave. *J Med Virol*. 2022;94(1):291-297. doi:10.1002/jmv.27319
8. Vahidy FS, Drews AL, Masud FN, et al. Characteristics and Outcomes of COVID-19 Patients During Initial Peak and Resurgence in the Houston Metropolitan Area. *JAMA*. 2020;324(10):998-1000. doi:10.1001/jama.2020.15301

1
2
3 9. Hoogenboom WS, Pham A, Anand H, et al. Clinical characteristics of the first
4 and second COVID-19 waves in the Bronx, New York: A retrospective cohort
5 study. *Lancet Reg Health Am*. 2021;3:100041. doi:10.1016/j.lana.2021.100041
6
7

8
9 10. Saito S, Asai Y, Matsunaga N, et al. First and second COVID-19 waves in Japan:
10 A comparison of disease severity and characteristics. *J Infect*. 2021;82(4):84-123.
11 doi:10.1016/j.jinf.2020.10.033
12
13

14
15 11 Borghesi A, Golemi S, Carapella N, Zigliani A, Farina D, Maroldi R. Lombardy,
16 Northern Italy: COVID-19 second wave less severe and deadly than the first? A
17 preliminary investigation. *Infect Dis (Lond)*. 2021;53(5):370-375.
18 doi:10.1080/23744235.2021.1884745
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table-1. Baseline epidemiological and clinical characteristics of patients during the first and second wave of the COVID – 19 pandemic

Variables	First wave (n=1039 n (%))	Second wave (n=991 n (%))	p- value
Age (In years)			
Mean \pm SD	44.90 \pm 9.99	44.34 \pm 9.57	0.194
18 - 35	202 (19.4)	192 (19.4)	0.896
36 - 50	550 (52.9)	535 (54)	
51 -- 65	265 (25.5)	247 (24.9)	
Above 65	22 (2.1)	17 (1.7)	
Gender			
Male	989 (95.2)	877 (88.5)	<0.001
Female	50 (4.8)	114 (11.5)	
Signs and symptoms			
Asymptomatic	48 (4.6)	94 (9.5)	<0.001
Mean duration of symptoms in days \pm SD	4.88 \pm 2.91	4.57 \pm 2.50	0.010
Fever	893 (85.9)	870 (87.8)	0.220
Respiratory symptoms	856 (82.4)	709 (71.5)	<0.001
Upper respiratory symptoms	192 (18.5)	358 (36.1)	<0.001
Cough	823 (79.2)	862 (87)	<0.001
Shortness of breath	286 (27.5)	377 (38)	<0.001
Chest pain	43(4.1)	37(3.7)	0.639
GI symptoms	88 (8.5)	66 (6.7)	0.124
Vomiting	50 (4.8)	38 (3.8)	0.280
Diarrhea	49 (4.7)	38 (3.8)	0.327
Co-Morbidities			
Immunosuppression	12 (1.2)	4 (0.4)	0.056
Chemotherapy	6 (0.6)	5 (0.5)	0.823

Diabetes Mellitus	307(29.5)	217 (21.9)	<0.001
Hypertension	270 (26)	263 (26.5)	0.777
Coronary artery disease	41 (3.9)	26 (2.6)	0.095
Chronic kidney disease	17 (1.6)	14 (1.4)	0.681
Cancer	5 (0.5)	5 (0.5)	0.940
Liver disease	3 (0.3)	6 (0.6)	0.283
COPD/Asthma	19 (1.8)	8 (0.8)	0.045
Body mass index (kg/m²)			
Mean ± SD	27.95 ±4.46	28.29 ± 4.83	0.263
< 18.5	1(0.2)	6 (1.1)	0.360
18.6 – 25	102 (24.5)	137 (25.4)	
25.1– 30	201 (48.2)	243 (45)	
>30	113 (27.1)	154 (28.5)	

Results are shown as number of cases and percentages (in parenthesis) or as means with ± standard deviations.

COPD-Chronic obstructive pulmonary disease

Table-2. Showing vital Signs and oxygen requirement

Variables		First wave (n=1039)	Second wave (n=991)	p- value
Temperature C ⁰ Mean ±SD	On admission	37.3±0.75	37.3± 0.72	0.976
	Maximum	38.1±0.89	38.2±0.88	0.024
p-- value		<0.001	<0.001	
Pulse rate (Beats per minute) Mean ±SD	On admission	89±14	88±13	0.439
	Maximum	102±11	103±11	0.164
p- value		<0.001	<0.001	
Respiratory Rate /min Mean ±SD	On admission	19±2	19±3	0.030
	Maximum	22±5	23±6	<0.001
p- value		<0.001	<0.001	
Spo2 (%)Mean ±SD	On admission	97±2	97±1	0.327
	Lowest	94±4	93±5	<0.001
p- value		<0.001	<0.001	
Patients received supplemental oxygen. Number (%)	On admission	238 (22.9)	399 (40.3)	<0.001
	After admission	315 (30.3)	394(39.8)	<0.001
p- value		<0.001	<0.001	

Table- 3. Showing laboratory parameters and chest X-ray findings

Variables	First wave Mean \pm SD	Second wave Mean \pm SD	p- value
WBC (10^3 /ul)	6.49 \pm 2.41	6.27 \pm 2.21	0.031
Hemoglobin (g/dl)	14.35 \pm 1.37	14.16 \pm 1.43	0.003
Platelet count (10^3 /ul)	234.99 \pm 89.44	225.55 \pm 82.50	0.014
Albumin (gm/L)	36.97 \pm 4.83	35.58 \pm 4.94	<0.001
C-Reactive Protein (mg/L)	50.54 \pm 53.28	33.68 \pm 44.20	<0.001
Lactate	1.74 \pm 0.77	1.73 \pm 0.91	0.924
Procalcitonin	0.41 \pm 1.62	0.30 \pm 1.15	0.284
D- Dimer	1.20 \pm 4.28	1.10 \pm 3.84	0.651
Aspartate aminotransferase (AST)	44.14 \pm 34.47	50.81 \pm 141.91	0.152
Alkaline phosphatase (ALP)	77.56 \pm 31.71	78.29 \pm 34.96	0.626
Alanine aminotransferase (ALT)	42.74 \pm 33.28	44.30 \pm 34.24	0.305
Total Bilurubin	9.97 \pm 5.73	9.57 \pm 6.20	0.143
HbA1c	7.37 \pm 2.04	6.94 \pm 1.83	<0.001
Chest X ray findings			
Unilateral infiltrations	185 (17.8)	236 (23.8)	0.001
Bilateral infiltrations	854 (82.2)	755 (76.2)	

Table -4. Showing the details of treatment received

Treatment	First wave (n=1039) n (%)	Second wave (n=991) n(%)	p-value
Dexamethasone	178 (17.1)	473 (47.7)	<0.001
Anticoagulation	1012 (97.4)	981 (99)	0.007
Favipiravir	230 (22.1)	704 (71)	<0.001
Hydroxychloroquine	920(88.5)	598 (60.3)	<0.001
Lopinavir/ ritonavir	369 (35.5)	630 (63.6)	<0.001
Anakinra	28 (2.7)	105 (10.6)	<0.001
Tocilizumab	21 (2.0)	19 (1.9)	0.866
Amoxicillin/clavulanic acid	633 (60.9)	290 (29.3)	<0.001
Ceftriaxone/ Cefuroxime	772 (74.3)	699 (70.5)	0.058
Azithromycin /Clarithromycin	770 (74.1)	415 (41.9) (6.9)	<0.001
Piperacillin /tazobactam	51 (4.9)	68	0.061

*One patient might have received more than one type of treatment

Table- 5. Showing final outcomes and disposition

Variables	First Wave (n=1030) n (%)	Second wave (n=991) n(%)	p-value
Mechanical ventilation	28 (2.7)	40 (4.0)	0.093
Pulmonary embolism/DVT	3 (0.3)	11 (1.1)	0.025
Death	3 (0.3)	8 (0.8)	0.112
Discharge disposition			
Discharge home	105 (10.1)	222 (22.4)	<0.001
Transfer to quarantine	879 (84.6)	705 (71.1)	
Transfer to higher center	55 (5.3)	64 (6.5)	
Length of stay in days			
Mean \pm SD	14.58 \pm 7.75	12.61 \pm 6.16	<0.001
0-7	227 (21.8)	126 (12.7)	<0.001
8-14	261 (25.1)	638 (64.4)	
15-30	529 (50.9)	212 (21.4)	
>30	22 (2.1)	15 (1.5)	

Figure legends

Figure 1.A-C. Box plot showing the distribution of age, duration of symptoms and BMI

Figure 2 A-D. Box plots depicting the vital signs

Figure 2.E-H. Box plots depicting the vital signs

Figure 3. A-F. Box plots depicting distribution laboratory parameters

Figure 3.G-K. Box plots depicting distribution laboratory parameters




Figure 1.A-C.

Review only




Figure 2 A-D.




Figure 2 E-H. Boxplots depicting the vital signs




Figure 3 A-F.




Figure 3 G-K.

Check list

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	4-5
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	6-7
Objectives	3	State specific objectives, including any prespecified hypotheses	7
Methods			
Study design	4	Present key elements of study design early in the paper	7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	7
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	NA
Study size	10	Explain how the study size was arrived at	NA
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	

Continued on next page

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8-11
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8-11
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	11
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	8-11
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA
Discussion			
Key results	18	Summarise key results with reference to study objectives	12-16
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	16-17
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12-16
Generalisability	21	Discuss the generalisability (external validity) of the study results	12-16
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	19

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Comparison of demographic, clinical and laboratory characteristics between first and second COVID-19 waves in a secondary care hospital in Qatar: A retrospective study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-061610.R1
Article Type:	Original research
Date Submitted by the Author:	24-May-2022
Complete List of Authors:	<p>NAUSHAD, VAMANJORE; Hamad Medical Corporation, Medicine; Qatar University College of Medicine PURAYIL, NISHAN; Hamad Medical Corporation, Medicine; Qatar University College of Medicine CHANDRA, PREM; Hamad Medical Corporation, MEDICAL RESEARCH CENTER Saeed, Abazar Ahmad M; Hamad Medical Corporation, Medicine Radhakrishnan, Pradeep; Hamad Medical Corporation, Medicine VARIKKODAN, IRFAN; Hamad Medical Corporation, Medicine Mathew, Joe V; Hamad Medical Corporation, Medicine; Qatar University College of Medicine Sirajudeen, Jaseem; Hamad Medical Corporation, Medicine; Qatar University College of Medicine Hammamy, Riyadh A; Hamad Medical Corporation, Medicine Badi, Ahmad M; Hamad Medical Corporation, Medicine; Qatar University College of Medicine Suliman, Aasir M; Hamad Medical Corporation, Medicine Badawi, Mohamed N; Hamad Medical Corporation, Department of Infectious Diseases Arya, Saket; Hamad Medical Corporation, Ophthalmology AlMotawa, Maryam; Qatar University College of Medicine Al-Baker, Aisha; Qatar University College of Medicine Alatom, Rania; Qatar University College of Medicine Kartha, Anand; Hamad Medical Corporation, Medicine; Weill Cornell Medicine - Qatar</p>
Primary Subject Heading:	Infectious diseases
Secondary Subject Heading:	Global health
Keywords:	COVID-19, EPIDEMIOLOGY, INFECTIOUS DISEASES

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open: first published as 10.1136/bmjopen-2022-061610 on 28 June 2022. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Title

Comparison of demographic, clinical and laboratory characteristics between first and second COVID-19 waves in a secondary care hospital in Qatar: A retrospective study

Key words

COVID-19 infection, Coronavirus, SARS-CoV-2, Pandemic, First wave, Second wave

For peer review only

Authors and affiliations

Vamanjore A Naushad^{1, 5}

Nishan K Purayil^{1, 5} Email-nishankp@live.com

Prem Chandra² Email-pchandra@hamad.qa

Abazar Ahmad M Saeed¹ Email-asaeed5@hamad.qa

Pradeep Radhakrishnan¹ Email-pradhakrishnan@hamad.qa

Irfan Varikkodan¹ Email-ivarikkodan@hamad.qa

Joe V Mathew^{1, 5} Email-jmathew13@hamad.qa

Jaseem Sirajudeen^{1, 5} Email-jsirajudeen@hamad.qa

Riyadh A Hammamy¹ Email-rhammamy@hamad.qa

Ahmad M Badi^{1, 5} Email-abadi@hamad.qa

Aasir M Suliman¹ Email-asuliman4@hamad.qa

Mohamed N Badawi³ Email-mmohamed21@hamad.qa

Saket Arya⁴ Email-sarya@hamad.qa

Maryam AlMotawa⁵ Email-malmotawa@hamad.qa

Aisha Al-Baker⁵ Email-aalbaker4@hamad.qa

Rania Alatom⁵ Email-Ra1601687@qu.edu.qa

Anand B Kartha^{1, 6} Email-akartha@hamad.qa

1
2
3
4
5
6
7
8
9 1- Department of Medicine

10
11 Hamad Medical Corporation

12
13 2- Medical Research Center

14
15 Hamad Medical Corporation

16
17 3- Department of Infectious Diseases

18
19 Hamad Medical Corporation

20
21 4- Department of Ophthalmology

22
23 Hamad Medical Corporation

24
25 5- College of Medicine- Qatar University

26
27 6-Weill Cornell Medicine-Qatar

28
29
30
31
32
33
34
35
36
37
38 **Corresponding Author**

39
40 V.A.Naushad

41
42 General Internal Medicine Department

43
44 Hamad General Hospital

45
46 Hamad Medical Corporation

47
48 Doha, Qatar

49
50 Email-nousha87@hotmail.com

51
52 Email-vnaushad@hamad.qa

Abstract

Objective: To compare the patient profile and outcomes in Qatar during the first and second waves of the COVID-19 pandemic. **Setting:** A retrospective observational study was conducted comparing the demographic, clinical, and laboratory characteristics of patients with COVID-19 infection admitted to a secondary care hospital, during the first and second waves of the pandemic. **Participants:** 1039 patients from the first wave and 991 from the second wave who had pneumonia on chest X-ray and had a confirmed SARS-CoV-2 infection by a real-time PCR test of a nasopharyngeal swab were included. Patients with a normal chest X-ray and those who had a negative PCR test despite a positive COVID-19 antigen test were excluded. **Outcome:** Length of stay, need for mechanical ventilation, final disposition and mortality were the key outcomes studied **Results:** Flu like symptoms (18.5 % in the first wave vs. 36.1 % in the second wave, $p < 0.001$), cough (79.2% vs.87%, $p < 0.001$) and dyspnea (27.5% vs. 38% $p < 0.001$) were more common in the second wave. Second wave patients had significantly higher respiratory rate, lower peripheral oxygen saturation, needed more supplemental oxygen and had higher incidence of pulmonary embolism. More patients received hydroxychloroquine and antibiotics during the first wave and more received steroids, antivirals and interleukin-1 antagonist during the second wave. The second wave had a shorter length of stay (14.58 ± 7.75 vs. 12.61 ± 6.16), $p < 0.001$) and more patients were discharged home (22% vs. 10% $p < 0.001$). **Conclusions:** Patients who presented during the second wave of Covid-19 pandemic appeared to be more ill clinically and based on their laboratory

1
2
3 parameters.They required shorter hospitalization and were more likely to be
4 discharged home. This could represent greater expertise in handling such patients
5 that was acquired during the first wave as well as use of more appropriate and
6 combination therapies during the second wave.
7
8
9
10
11
12
13
14
15

16 **Strengths**

- 17 ● First study in the region to compare patient characteristics between the two
18 waves
19
- 20 ● All patient variables were compared, including demographics, clinical
21 complaints, vital signs, laboratory indicators, and outcomes.
22
23
24
25
26
27
28

29 **Limitations**

- 30 ● The relationship between risk factors and outcomes was not investigated.
31
32
33
- 34 ● Patients with severe COVID-19 were not included
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Corona virus disease 2019 (COVID-19), first identified in the Wuhan province of China, was declared a global pandemic by the World Health Organization (WHO) on 11 March, 2020 [1]. To date, it has affected 521,920,560 with more than 6 million deaths worldwide. In Qatar, COVID-19 infection has affected 367,099 individuals with 677 deaths till May 2022 [2]. On 29 February 2020 Qatar reported its first confirmed case of COVID-19 infection. During the first and second wave maximum number of cases was reported between 16 April 2020 and 20 July 2020 and between 8 February 2021 and 8 June 2021 respectively.

The virus responsible for the COVID-19 infection is Severe acute respiratory syndrome corona virus (SARS-CoV-2), a novel corona virus belonging to the family Coronaviridae[3].The initial outbreak in China was thought to be originated by zoonotic spread from the seafood markets in the Wuhan province. Afterwards human-to-human transmission was recognized for the community spread of the disease, which rapidly became a global infection leading to the pandemic [4-7].

The mode of transmission of the virus from person to person is via respiratory droplets. Transmission may also occur through fomites such as bed linen, thermometers etc used by the COVID-19 infected patients. Airborne spread has been reported from aerosol generating procedures such as endotracheal intubation, bronchoscopy, open suctioning, tracheostomy, and nebulization [8, 9].

The spectrum of clinical manifestations of COVID-19 infection ranges from asymptomatic infection to symptomatic presentation. A systematic review done before the introduction of the COVID-19 vaccination reported that 33% of COVID -

1
2
3 19 infections are asymptomatic [10]. However these asymptomatic individuals
4
5 can have radiological findings of ground glass opacities or patchy infiltrations in
6
7 CT scan [11] . Most common symptoms of presentations are fever, malaise,
8
9 myalgia, shortness of breath, and dry cough. Gastrointestinal symptoms may also
10
11 be found in some patients with COVID-19 infection [12, 13].
12
13

14
15 The severity of symptomatic disease might vary from mild disease which accounts
16
17 for the majority of the cases to severe or critical illness. Patients with severe
18
19 disease may have dyspnea, hypoxia or radiological imaging demonstrating more
20
21 than 50% involvements of lungs whereas; patients with critical disease will have
22
23 features of shock, respiratory or multi organ failure [14-18]. A report from
24
25 Centers for Disease Control and Prevention (CDC) from United States on
26
27 1.3million cases reported a cumulative incidence of 403.6 cases per 100,000
28
29 persons. The incidence was higher among patients more than 80 years of age.
30
31 Cardiovascular disease (32%) and diabetes mellitus (30%) were the most common
32
33 co-morbid conditions noted. Overall 14% were hospitalized, 2% were admitted to
34
35 the ICU and 5% died. The hospitalization and death were 6 times and 12 times
36
37 respectively higher among patients with underlying co-morbidities than those
38
39 without [19].
40
41
42
43

44 During the first wave the Government of Qatar introduced strict preventive
45
46 measures starting from March 2020, which included closure of all educational
47
48 institutions and commercial establishments, closure of public and private offices,
49
50 restaurants, banning of social gatherings, sports and entertainment activities, ban
51
52 on international travel and strict home confinement. Wearing face mask in public
53
54 space was made mandatory. As the number of cases in the first wave began to
55
56
57
58
59

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

recede, the restrictions were lifted in a phased manner from second half of June 2020. During the second wave when the number of cases started to raise the government reintroduced some of the preventive measures to contain the disease starting from February 2021. There was closure of parks, cinemas, sports activities. The public and private offices were allowed work with not more than 50% of capacity and there was ban on social gatherings however there was no complete lockdown.

During both pandemic waves, Ras Laffan Hospital, a secondary care hospital, was one of the COVID-19 designated hospitals under Hamad Medical Corporation (HMC). If patients met the admission criteria, they were transferred to Ras Laffan Hospital from non-COVID hospitals and tertiary care COVID facilities. During the first and second waves, respectively, 3650 and 4050 patients with a confirmed SARS-CoV-2 infection were hospitalized and treated at the Ras Laffan hospital.

From the time it was originally discovered in Wuhan, the disease profile, epidemiology, and treatment guidelines for COVID-19 infection had evolved continuously. On the basis of the most recent scientific findings, WHO released and updated diagnostic and treatment guidelines, as well as quarantine guidelines, on a regular basis. Countries around the world revised their management and quarantine standards on a regular basis based on this and locally available data.

Although the data on first 5000 cases of COVID-19 infection in Qatar have been reported [20], there is a lack of published literature comparing the epidemiology and consequences of repeated waves of the COVID-19 pandemic across the Middle East area, including Qatar. Furthermore, Qatar's population is made up

1
2
3 mostly of people of diverse countries and ethnic backgrounds. Hence, we chose to
4 investigate and compare the characteristics and outcomes in both waves to
5
6 better understand and manage future events
7
8
9

10 **Objective**

11
12 The goal of this study was to examine the patient profile and outcomes in COVID-
13
14 19-infected hospitalized patients during the first and second waves of the
15
16 pandemic.
17
18
19

20 **Methods**

21 **Study type and setting**

22
23 A retrospective observational study was conducted at Ras Laffan hospital, Hamad
24
25 Medical Corporation, Qatar. This hospital was one of the COVID-19 designated
26
27 hospitals under HMC.
28
29
30
31
32
33

34 **Study participants and sample selection**

35
36 Patients admitted between 1st to 30th of May 2020 in the first wave (n=1039) and
37
38 those admitted between 1st and 15th of March 2021 during the second wave
39
40 (n=991) were included in the study. The duration of the recruitment of patients
41
42 was shorter in the second wave in order to make it comparable and equal number
43
44 with the first wave. Though we did not use random sampling technique to select
45
46 patients, it is worth to note that all the patients who met the inclusion criteria
47
48 within the specified period were included. The patients were included if they had
49
50 pneumonia on chest X-ray and had a laboratory-confirmed SARS-CoV-2 infection
51
52 by a real-time PCR test of a nasopharyngeal swab specimen. The study excluded
53
54
55
56
57
58
59
60

1
2
3 patients with a normal chest X-ray and those who had a negative PCR test despite
4 a positive COVID-19 antigen test.
5
6
7

8 **Patient and public involvement** 9

10
11 No patient involved
12
13

14 **Data collection** 15

16
17 Using the patients' health care numbers, files from the clinical information system
18 were reviewed. Data was collected on demographics, admission symptoms, co-
19 morbidities, length of stay, laboratory and radiographic results, need for
20 supplemental oxygen, treatment details, complications, and outcomes.
21
22
23
24
25
26

27 **Outcome of the study** 28

29
30 The need for mechanical ventilation, length of stay, final disposition and mortality
31 were the key outcomes studied along with their clinical and laboratory
32 characteristics.
33
34
35
36
37

38 **Statistical analysis** 39

40
41 Descriptive statistics were used to summarize demographic, anthropometric,
42 clinical, laboratory, radiological characteristics, and related follow-up outcome
43 measures of these patients. Continuous variables with normal distribution were
44 presented as mean and standard deviation (SD), whereas median and
45 interquartile range (IQR) was used in case of skewed/non-normal data.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 statistical analysis method for outcomes measured quantitatively and differences
4 between the two independent groups (first and second COVID-19 waves) were
5 compared using unpaired t or Mann Whitney U tests as appropriate depending on
6 the normality of the data distribution. Associations between two or more
7 qualitative or categorical variables across two independent groups were
8 compared using Pearson Chi-square or Fisher exact test as applicable. Box plots
9 were constructed to depict distribution of age, duration of symptoms, BMI, vital
10 signs, and various parameters related to laboratory profiles across both groups
11 (first and second COVID-19 waves). All P values presented were two-tailed, and P
12 values <0.05 was considered as statistically significant. All Statistical analyses
13 were performed using statistical packages SPSS version 27.0 (Armonk, NY: IBM
14 Corp) and Epi-info (Center for Disease Control and Prevention, Atlanta, GA)
15 software.

31 **Results**

35 **Baseline demographic characteristics**

36
37
38 During the first and second waves, respectively, 3650 and 4050 patients with a
39 confirmed SARS-CoV-2 infection were hospitalized. The study included 1039
40 patients from the first wave and 991 participants from the second wave. During
41 both waves, the average age of the subjects was similar [44.9 ±9.9 vs.
42 44.34±9.56]. In both waves, the proportion of patients among various age groups
43 was comparable, with the majority of patients being between the ages of 36 and
44 50. (52.9 % vs.54.0 %). Males made up 95.2 % of the first wave and 88.5 % of the
45 second wave patients (Table 1).
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Clinical characteristics on admission

In the first wave patients had longer duration of symptoms prior to admission compared to second wave (4.88 ± 2.91 vs. 4.57 ± 2.50 , $p = 0.010$). Flu like symptoms (36.1% in the second wave vs. 18.5% in the first wave, $p < 0.001$), cough (87% vs. 79.2%, $p < 0.001$), and shortness of breath (38% vs. 27.5%, $p < 0.001$), were significantly higher in the second wave than the first. We did not find any significant difference in gastrointestinal symptoms between the two waves.

Diabetes mellitus (29.5% vs. 21.9%) and hypertension (26 % vs. 26.5%) were the most common co-morbid conditions observed in both waves; however, frequency of diabetes mellitus was significantly higher in the first wave ($p < 0.001$)

The mean body mass index (BMI) was 27.95 ± 4.46 and 28.29 ± 4.83 in the first and second waves, respectively ($p = 0.263$). Most patients had higher BMI in both the waves, with the majority having a BMI between 25.1 to 30 (48.2% vs. 45%) followed by more than 30 (27.1% vs. 28.5%) (Table-1). The details of distribution of age, duration of symptoms and BMI are plotted in Figure 1 A-C.

Vital signs and oxygen requirement

Patients in the second wave had significantly higher respiratory rate (23 ± 6 vs. 22 ± 5 , $p < 0.001$) and significantly lower peripheral oxygen saturation (93 ± 5 vs. 94 ± 4 , $p < 0.001$) when compared to the first wave. Furthermore, during the second wave significantly higher number of patients received supplemental oxygen on admission (40.3% vs. 22.9 %, $p < 0.001$) and also during their stay in the hospital (39.8% vs. 30.3%, $p < 0.001$). During the stay in the hospital there was significant variation in the vital parameters of the patients within the group from admission

value to their respective maximum/minimum values ($p < 0.001$) Table- 2 and figure 2 A-H.

Laboratory parameters and chest X-ray findings

The first wave had significantly higher C-reactive protein) (median 35.4, IQR 12.9, 72 vs. median 15.2, IQR 15.2, 32.2, $p < 0.001$ and HbA1c values (7.37 ± 2.04 vs. 6.94 ± 1.83 $p < 0.001$). The mean values of white blood cell count (6.49 ± 2.41 vs. 6.27 ± 2.21 , $p = 0.031$), hemoglobin (14.35 ± 1.37 vs. 14.16 ± 1.43 , $p = 0.003$), and platelet counts (234.99 ± 89.44 vs. 225.55 ± 82.50 , $p = 0.014$) were lower in the second wave than the first. The patients in the second wave, had considerably lower mean albumin levels than the first wave (35.58 ± 4.94 vs. 36.97 ± 4.83 , $p < 0.001$). Patients in the second wave had higher hepatic transaminases and alkaline phosphatase levels than the first wave, although the differences were statistically insignificant. In both waves, the majority of patients had bilateral pneumonia on chest x-ray. Table- 3 and figure 3 A-K.

Treatment received

In the first wave, the usage of amoxicillin/clavulanic acid (60.9% vs. 29.3%) and azithromycin/clarithromycin (74.1% vs. 41.9%) and usage of hydroxychloroquine (88.5% vs. 60.3%, $p < 0.001$) was higher.

A significantly higher number of patients in the second wave received steroids (47.7% vs. 17.1%, $p < 0.001$), favipiravir (71% vs. 22.1%, $p < 0.001$) or lopinavir/ritonavir (63.6% vs. 35.5%, $p < 0.001$ and anakinra (10.6% vs. 2.7%, $p < 0.001$).

1
2
3 Similar number of patients in both the waves received cephalosporins (74.3% vs.
4 70.5%, $p=0.058$) and prophylactic anticoagulation (97.4% vs. 99%).Table - 4.
5
6
7

8 **Complications/ outcome and disposition**

9
10
11 In the first and second waves, 5.3% and 6.5 %of patients, respectively, required
12 transfer to a higher center for further care. Among those who were transferred,
13 28 (2.7%) patients in the first wave and 40 (4%) in the second wave received
14 mechanical ventilation ($p= 0.093$). In the second wave, the percentage of patients
15 who developed pulmonary embolism was significantly higher (1.1 % vs. 0.03%,
16 $p=0.025$), furthermore, a higher proportion of mortality (0.81% (8/991) vs. 0.3%
17 (3/1030)) was recorded in the second wave, however this difference was
18 statistically insignificant ($p=0.112$).
19
20
21
22
23
24
25
26
27
28

29
30 In the second wave, the average length of stay was 1.9 days shorter which was
31 statistically significant (14.58 ± 7.75 vs. 12.61 ± 6.16 , $p < 0.001$). The majority of
32 patients in the first wave stayed for 15 to 30 days (50.9 % vs. 21.4%), while the
33 majority of patients in the second wave stayed for 8 to 14 days (64.4% vs.
34 25.15%), table 5.
35
36
37
38
39
40

41 There was significantly higher percentage of patients who were transferred to
42 quarantine facility in the first wave than the second wave (84.6% vs. 71.1%,
43 $p < 0.001$) where as significantly higher percentage of patients were discharged to
44 their home in the second wave than the first wave (22.4% vs 10.1%, $p < 0.001$).
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

To our knowledge, this is the first study from the state of Qatar to compare COVID-19 individuals hospitalized between the first and second waves of the SARS-CoV-2 pandemic. Our findings show a significant variation between the two waves in terms of clinical features, laboratory markers and outcomes.

There was no difference in the average age of the patients between the two waves. In confirmation to our findings, a previous study conducted in Switzerland by Wolfsburg et al. [21] found no difference in the mean age of patients between two waves (65.9 vs. 65.8 years), whereas in contrast to our results a study by Iftimie et al. from Spain [22] found that the patients in the second wave were significantly younger than the first wave (58 years vs. 67 years). Our research sample, however, was substantially younger in both waves [44.90 9.99 vs. 44.34 9.57] than the previous two study groups. The young male expatriate workforce makes up the bulk of Qatar's population, which might explain this. We predicted the duration of symptoms prior to admission to be longer in the second wave than in the first because the patients were more apprehensive and sought medical assistance earlier in the first wave than in the second. Furthermore, the knowledge acquired and improved understanding of the COVID-19 disease epidemiology gained from handling the first wave should have given health practitioners the confidence to manage patients with mild to moderate disease at home rather than in the hospital during the second wave. Our findings, on the other hand, revealed that the duration of symptoms before to admission was longer in the first wave than in the second.

1
2
3
4 On admission to the hospital cough, shortness of breath and upper respiratory
5 symptoms were more common in the second wave. The patients in the second
6 wave had more symptoms and were sicker as evidenced by tachypnea and
7 hypoxia and more patients requiring oxygen. We did not observe a significant
8 difference in the prevalence of gastrointestinal symptoms between both the
9 waves. This is in contrast to previous research [22, 23], which reported a higher
10 prevalence of gastrointestinal complaints in the in the second wave.
11
12
13
14
15
16
17
18

19 The most common co-morbidities in both waves of the research population were
20 diabetes mellitus and hypertension. The number of diabetes patients, on the
21 other hand, was much higher in the first wave. One possible explanation for the
22 lower number of diabetes mellitus patients in the second wave is that health
23 advice given by the WHO as well as published literature showing evidence of
24 diabetes mellitus as a risk factor for having the severe disease made these
25 patients more cautious and isolate themselves, thereby shielding and protecting
26 them from being exposed to infected patients. When comparing co-morbidities in
27 both the waves, previous research have yielded conflicting outcomes. Iftimie et
28 al. [22] showed no significant differences in co-morbidity between the two waves,
29 however Jarrett et al. [24] and Sargin et al. [25] identified a higher frequency of
30 chronic kidney illness in the second wave than in the first wave.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46 Despite the fact that the mean BMI did not alter significantly between the two
47 waves, the majority of our research group had a higher BMI in both, suggesting
48 obesity as a probable risk factor for COVID-19 infection. However this needs
49 further studies analyzing the correlation between obesity as a risk factor and
50 Covid-19 infection. Obesity was found in 30% of the whole study population in
51
52
53
54
55
56
57
58
59
60

1
2
3 both waves, according to a study from Switzerland [21]. Another study from the
4 United States [24] found that the second wave had a higher BMI than the first
5 wave (32.58 vs. 29.83).
6
7
8

9
10 The study of laboratory measurements revealed that the first wave had higher
11 mean values of CRP and HbA1c, while hypoalbuminemia was significantly higher
12 in the second wave. Furthermore levels of leukocyte and platelet count were
13 lower in second wave than the first wave. The second wave had higher mean
14 levels of hepatic transaminases but the difference was statistically not significant.
15 The higher HbA1c readings in the first wave are unsurprising given the higher
16 prevalence of diabetes mellitus in the first wave compared to the second wave.
17 The higher hepatic transaminases in the second wave could be due to a variety of
18 factors. One probable reason could be secondary to the side effect of favipiravir,
19 as it was used more frequently in the second wave than in the first wave.
20
21
22
23
24
25
26
27
28
29
30
31
32

33 In our study population, the use of steroids was much higher in the second wave
34 [47% vs. 17%]. This is because during the early stage of the first wave scientific
35 literature regarding the benefit of steroids in COVID-19 infection was still in its
36 preliminary stage and its use was limited. The frequency of usage of steroids in
37 published data was still greater (99% [24], 76% [21]) than ours in the second
38 wave. Because the aforementioned two studies included individuals with more
39 severe disease than our research sample, the frequency of steroid administration
40 differed. In terms of prophylactic anticoagulation, practically more than 97% of
41 the patients in both waves received anticoagulation in our research group. This
42 was much greater than the 59% in the first wave and 74% in the second wave
43 reported in a research conducted in the United States [24].
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 The usage of hydroxychloroquine was significantly higher in the first wave,
4 whereas the use of favipiravir and anakinra was much higher in the second wave,
5 according to our findings. This is because treatment guidelines evolved and
6 modified from the first wave to the second wave based on published scientific
7 information around the world. Furthermore, use of antibiotics was significantly
8 higher in the first wave than the second wave. There are multiple reasons for this.
9
10 First, during the first wave azithromycin was more commonly used along with
11 hydroxychloroquine as a treatment for COVID-19 infection. Second, due to lack of
12 experience and expertise in managing the COVID-19 pandemic antibiotics were
13 more commonly prescribed for patients with COVID pneumonia during the first
14 wave; however during the second wave clinicians acquired adequate knowledge
15 and experience and were more confident to treat patients without antibiotics
16 unless indicated.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

32 Despite the fact that patients in the second wave were sicker as evidenced by
33 more symptoms, tachypnea and hypoxia on admission and laboratory
34 parameters, the duration of hospitalization were significantly lower in the second
35 wave. In the present study the average length of stay in the second
36 wave was nearly 2 days less than in the first. This supports the findings of other research
37 [21, 22, 25], which similarly found a shorter length of stay in the second wave. In
38 addition more patients were discharged home in the second wave than
39 transferred to quarantine facility. Possible explanation for this could be the
40 change in discharge/transfer criteria. Secondly, better understanding of the
41 disease course and experience of managing the first wave made the health care
42 professionals more confident in early discharge of patients in the second wave.
43
44 Finally, better home surveillance of discharged patients, development of better
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 follow up care, and community awareness and education might have also played
4 an important role.
5
6

7
8 Even while the number of patients who needed to be transferred to a higher
9 center, those who needed mechanical ventilation, had a pulmonary embolism and
10 those who died were all somewhat higher in the second wave than in the first, the
11 difference was not statistically significant. Available published data from two
12 studies, one from Switzerland [21] and another from Turkey [25] found no
13 significant difference in the proportion of patients requiring or at risk for Intensive
14 Care Unit (ICU) admission in both the waves. However, the percentage of patients
15 needing ICU care in the above two studies was higher than our results in both the
16 waves. This could be related to the fact that our study and theirs had different
17 severity of cases and also could be due to the difference in admission criteria in
18 our study and others. Our admission criteria included patients with pneumonia
19 requiring less than 4 L of oxygen at the time of admission, whereas other studies
20 included more severe cases or ICU cases. Others have reported similar results,
21 finding no substantial change in the number of patients requiring mechanical
22 ventilation in both waves [24, 25]. There was no significant change in mortality
23 rates between the two waves in the present study. Previous research comparing
24 mortality rates between the two COVID-19 pandemic waves came up with mixed
25 results. Our findings are consistent with those of Wolfisberg et al.[21] and Sargin
26 et al. [25], who found no difference in mortality rates between the two waves,
27 but Iftimie et al.[22] and Jarrett et al.[24] reported lower mortality in the second
28 wave, in contrast to our findings. Similarly, two studies from the United States
29 found that the second wave had a reduced mortality rate [26, 27]. According to
30 published statistics from Japan based on a public registry reported that the
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 second wave of patients were younger, had fewer underlying co-morbidities, and
4 had lower mortality rates [28].
5
6
7

8 A few studies from Europe also found lower mortality in the second wave. Chest
9 X-ray severity of pneumonia, in-hospital mortality, and CRP readings were
10 considerably greater in the first wave, according to an Italian study involving 200
11 Caucasian males over 50 years. They also discovered that the first wave had more
12 patients who required mechanical ventilation [29]. Another study from Spain
13 found that the second wave had younger patients, a shorter duration of stay in
14 the hospital, fewer invasive mechanical ventilation, and decreased mortality [22].
15
16
17
18
19
20
21
22
23

24 The first wave's experience and lessons acquired by health care professionals, as
25 well as a collaborative team effort involving numerous government agencies and
26 community awareness and engagement, have helped us to manage the second
27 wave more effectively.
28
29
30
31
32
33

34 **Limitations**

35
36
37 There were certain limitations to our research. To begin with, some data on co-
38 morbidity and symptoms may have been overlooked due to the retrospective
39 nature of the study. Second, there might have been selection bias because our
40 research population was mostly male patients as most female COVID-19 patients
41 were admitted to other COVID designated hospitals. Third, because our research
42 sample included only mild to moderate Covid-19 infections, the findings may not
43 be generalized to severe COVID -19 infections. Finally, the relationship between
44 risk variables and outcomes was not examined as it was not the primary goal of
45 our study.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Recommendation for future research

Future study should compare the relationship between various risk variables and outcomes over serial COVID-19 waves. Long-term consequences of COVID-19 infection in the first and second waves can also be studied and compared.

Conclusions

Patients in the second wave were more symptomatic and unwell than those in the first wave, but they stayed in the hospital for a shorter time and were more likely to be discharged home, according to our data. The most prevalent symptoms in both waves were cough and shortness of breath, although they were much greater in the second wave. Diabetes mellitus and raised CRP levels were more common in the first wave, but hypoalbuminemia was more prevalent in the second wave. In the first wave, antibiotics and hydroxychloroquine were more commonly utilized, but in the second wave, steroids, antivirals, and interleukin-1 antagonists were more commonly employed. There was no significant difference in the need for mechanical ventilation or mortality rate between the two waves.

Author's contribution

VN- Study design, data collection, analysis, manuscript writing, editing

NP- Study design, data collection, analysis, manuscript writing, editing

PC- Study design, data analysis, editing

AS- Data collection, analysis

PR- Data collection, analysis

IV- Study design, editing

JM- Analysis, manuscript writing

JS- Data collection, literature review

RH- Data collection, manuscript writing

AB- Data collection, manuscript writing

AA- Data collection, editing

MB- Data analysis, manuscript writing

SA- Data collection, manuscript writing

MA- Data collection, editing

AA- Data collection, literature review

RA- Data collection, literature review

AK- Data analysis, manuscript writing, editing

Acknowledgement

Nil

Competing interests' statement

The authors declare that they have no competing interest involved

Funding

1
2
3 This research received no specific grant from any funding agency in the public, commercial or
4
5 not-for-profit sectors
6

7
8 **Data sharing statement**
9

10 No additional data available
11

12 **Ethical approval**
13

14 The study was approved by the Institutional Review Board and institutional research committee
15
16 of medical research center, Hamad, Medical Corporation (Approval no-MRC-01-21-312).
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. <https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19>
2. <https://covid19.moph.gov.qa/EN/Pages/default.aspx>
3. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: a review [published online ahead of print, 2020 Apr 20]. *Clin Immunol*. 2020; 215:108427)
4. Parasher A. COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. *Postgrad Med J*. 2021 May;97(1147):312-320. doi: 10.1136/postgradmedj-2020-138577. Epub 2020 Sep 25. PMID: 32978337.
5. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. *N Engl J Med* 2020;382:1199–207.
6. Zheng M, Gao Y, Wang G, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. *Cell Mol Immunol* 2020.
7. Zhang J, Litvinova M, Wang W, et al. Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study. *Lancet Infect Dis* 2020;20:793–802.)
8. Burke RM, Midgley CM, Dratch A, et al. Active monitoring of persons exposed to patients with confirmed COVID-19: United States, January–February 2020. *MMWR Morb Mortal Wkly Rep* 2020
9. Ong SW, Tan YK, Chia PY, et al. Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient. *JAMA* 2020;323:1610).
10. Oran DP, Topol EJ. The Proportion of SARS-CoV-2 Infections That Are Asymptomatic : A Systematic Review. *Ann Intern Med*. 2021 May;174(5):655-662. doi: 10.7326/M20-6976. Epub 2021 Jan 22. PMID: 33481642; PMCID: PMC7839426

- 1
2
3 11. Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, Ma H, Chen W, Lin Y, Zheng Y, Wang J, Hu Z, Yi Y,
4 Shen H. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among
5 close contacts in Nanjing, China. *Sci China Life Sci.* 2020 May;63(5):706-711. doi:
6
7 10.1007/s11427-020-1661-4. Epub 2020 Mar 4. PMID: 32146694; PMCID: PMC7088568
8
9
10
11 12. Cheung KS, Hung IF, Chan PP, et al. Gastrointestinal manifestations of SARS-CoV-2 infection
12 and virus load in fecal samples from the hong kong cohort and systematic review and meta-
13 analysis. *Gastroenterology* 2020;
14
15
16
17 13. Available <https://www.webmd.com/lung/COVID19-digestive-symptoms> .
18
19
20
21 14. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J,
22 Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q,
23 Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan,
24 China. *Lancet.* 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub
25 2020 Jan 24. Erratum in: *Lancet.* 2020 Jan 30;: PMID: 31986264; PMCID: PMC7159299.
26
27
28
29
30
31 15. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang
32 X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus
33 pneumonia in Wuhan, China: a descriptive study. *Lancet.* 2020 Feb 15;395(10223):507-513. doi:
34 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30. PMID: 32007143; PMCID: PMC7135076.
35
36
37
38
39 16. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y,
40 Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel
41 Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA.* 2020 Mar 17;323(11):1061-1069. doi:
42 10.1001/jama.2020.1585. Erratum in: *JAMA.* 2021 Mar 16;325(11):1113. PMID: 32031570;
43
44
45
46
47
48
49 17. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y, Pan S, Zou
50 X, Yuan S, Shang Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2
51 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet*
52
53
54
55
56
57
58
59
60

1
2
3 Respir Med. 2020 May;8(5):475-481. doi: 10.1016/S2213-2600(20)30079-5. Epub 2020 Feb 24.
4 Erratum in: Lancet Respir Med. 2020 Apr;8(4):e26. PMID: 32105632; PMCID: PMC7102538.
5
6

7
8 18. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus
9 Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the
10 Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7;323(13):1239-1242. doi:
11 10.1001/jama.2020.2648. PMID: 32091533. 020).
12
13
14

15
16 19. Stokes EK, Zambrano LD, Anderson KN, Marder EP, Raz KM, El Burai Felix S, Tie Y, Fullerton
17 KE. Coronavirus Disease 2019 Case Surveillance - United States, January 22-May 30, 2020.
18 MMWR Morb Mortal Wkly Rep. 2020 Jun 19;69(24):759-765. doi: 10.15585/mmwr.mm6924e2.
19 PMID: 32555134; PMCID: PMC7302472.
20
21
22

23
24 20. Omrani AS, Almaslamani MA, Daghfal J, Alattar RA, Elgara M, Shaar SH, Ibrahim TBH, Zaqout
25 A, Bakdach D, Akkari AM, Baiou A, Alhariri B, Elajez R, Husain AAM, Badawi MN, Abid FB, Abu
26 Jarir SH, Abdalla S, Kaleeckal A, Choda K, Chinta VR, Sherbash MA, Al-Ismaail K, Abukhattab M,
27 Ait Hssain A, Coyle PV, Bertollini R, Frenneaux MP, Alkhal A, Al-Kuwari HM. The first consecutive
28 5000 patients with Coronavirus Disease 2019 from Qatar; a nation-wide cohort study. BMC
29 Infect Dis. 2020 Oct 19;20(1):777. doi: 10.1186/s12879-020-05511-8. PMID: 33076848; PMCID:
30 PMC7570422.
31
32
33
34
35
36

37
38 21. Wolfisberg S, Gregoriano C, Struja T, et al. Comparison of characteristics, predictors and
39 outcomes between the first and second COVID-19 waves in a tertiary care centre in
40 Switzerland: an observational analysis. *Swiss Med Wkly*. 2021;151:w20569. Published 2021 Aug
41 10. doi:10.4414/smw.2021.20569
42
43
44

45 22. Iftimie S, López-Azcona AF, Vallverdú I, et al. First and second waves of coronavirus disease-
46 19: A comparative study in hospitalized patients in Reus, Spain. *PLoS One*.
47 2021;16(3):e0248029. Published 2021 Mar 31. doi:10.1371/journal.pone.0248029
48
49

50 23. Jalali SF, Ghassemzadeh M, Mouodi S, et al. Epidemiologic comparison of the first and
51 second waves of coronavirus disease in Babol, North of Iran. *Caspian J Intern Med*.
52 2020;11(Suppl 1):544-550. doi:10.22088/cjim.11.0.544
53
54
55
56
57
58
59
60

- 1
2
3 24. Jarrett SA, Lo KB, Shah S, et al. Comparison of Patient Clinical characteristics and Outcomes
4 Between Different COVID-19 Peak Periods: A Single Center Retrospective Propensity Matched
5 Analysis. *Cureus*. 2021;13(6):e15777. Published 2021 Jun 20. doi:10.7759/cureus.15777
6
7
8 25. Sargin Altunok E, Satici C, Dinc V, et al. Comparison of demographic and clinical
9 characteristics of hospitalized COVID-19 patients with severe/critical illness in the first wave
10 versus the second wave. *J Med Virol*. 2022;94(1):291-297. doi:10.1002/jmv.27319
11
12
13 26. Vahidy FS, Drews AL, Masud FN, et al. Characteristics and Outcomes of COVID-19 Patients
14 During Initial Peak and Resurgence in the Houston Metropolitan Area. *JAMA*. 2020;324(10):998-
15 1000. doi:10.1001/jama.2020.15301
16
17
18 27. Hoogenboom WS, Pham A, Anand H, et al. Clinical characteristics of the first and second
19 COVID-19 waves in the Bronx, New York: A retrospective cohort study. *Lancet Reg Health Am*.
20 2021;3:100041. doi:10.1016/j.lana.2021.100041
21
22
23 28. Saito S, Asai Y, Matsunaga N, et al. First and second COVID-19 waves in Japan: A comparison
24 of disease severity and characteristics. *J Infect*. 2021;82(4):84-123.
25 doi:10.1016/j.jinf.2020.10.033
26
27
28 29. Borghesi A, Golemi S, Carapella N, Zigliani A, Farina D, Maroldi R. Lombardy, Northern Italy:
29 COVID-19 second wave less severe and deadly than the first? A preliminary investigation. *Infect*
30 *Dis (Lond)*. 2021;53(5):370-375. doi:10.1080/23744235.2021.1884745
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table-1. Baseline epidemiological and clinical characteristics of patients during the first and second wave of the COVID – 19 pandemic

Variables	First wave (n=1039 n (%))	Second wave (n=991 n (%))	p- value
Age (In years)			
Mean \pm SD	44.90 \pm 9.99	44.34 \pm 9.57	0.194
18 - 35	202 (19.4)	192 (19.4)	0.896
36 - 50	550 (52.9)	535 (54)	
51 -- 65	265 (25.5)	247 (24.9)	
Above 65	22 (2.1)	17 (1.7)	
Gender			
Male	989 (95.2)	877 (88.5)	<0.001
Female	50 (4.8)	114 (11.5)	
Signs and symptoms			
Asymptomatic	48 (4.6)	94 (9.5)	<0.001
Mean duration of symptoms in days \pm SD	4.88 \pm 2.91	4.57 \pm 2.50	0.010
Fever	893 (85.9)	870 (87.8)	0.220
Respiratory symptoms	856 (82.4)	709 (71.5)	<0.001
Flu like symptoms	192 (18.5)	358 (36.1)	<0.001
Cough	823 (79.2)	862 (87)	<0.001
Shortness of breath	286 (27.5)	377 (38)	<0.001
Chest pain	43(4.1)	37(3.7)	0.639
GI symptoms	88 (8.5)	66 (6.7)	0.124
Vomiting	50 (4.8)	38 (3.8)	0.280
Diarrhea	49 (4.7)	38 (3.8)	0.327
Co-Morbidities			
Immunosuppression	12 (1.2)	4 (0.4)	0.056
Chemotherapy	6 (0.6)	5 (0.5)	0.823

Diabetes Mellitus	307(29.5)	217 (21.9)	<0.001
Hypertension	270 (26)	263 (26.5)	0.777
Coronary artery disease	41 (3.9)	26 (2.6)	0.095
Chronic kidney disease	17 (1.6)	14 (1.4)	0.681
Cancer	5 (0.5)	5 (0.5)	0.940
Liver disease	3 (0.3)	6 (0.6)	0.283
COPD/Asthma	19 (1.8)	8 (0.8)	0.045
Body mass index (kg/m²)			
Mean ± SD	27.95 ±4.46	28.29 ± 4.83	0.263
< 18.5	1(0.2)	6 (1.1)	0.360
18.6 – 25	102 (24.5)	137 (25.4)	
25.1– 30	201 (48.2)	243 (45)	
>30	113 (27.1)	154 (28.5)	

Results are shown as number of cases and percentages (in parenthesis) or as means with ± standard deviations.

COPD-Chronic obstructive pulmonary disease

For statistical analysis first wave was compared with the second wave. Quantitative data were compared using t test (normal data distribution) and Mann Whitney U test for skew data distribution. Qualitative data were compared using Chi-square test.

Table-2. Showing vital Signs and oxygen requirement

Variables		First wave (n=1039)	Second wave (n=991)	p- value
Temperature C ⁰ Mean ±SD	On admission	37.3±0.75	37.3± 0.72	0.976
	Maximum	38.1±0.89	38.2±0.88	0.024
p-- value		<0.001	<0.001	
Pulse rate (Beats per minute) Mean ±SD	On admission	89±14	88±13	0.439
	Maximum	102±11	103±11	0.164
p- value		<0.001	<0.001	
Respiratory Rate /min Mean ±SD	On admission	19±2	19±3	0.030
	Maximum	22±5	23±6	<0.001
p- value		<0.001	<0.001	
Spo2 (%)Mean ±SD	On admission	97±2	97±1	0.327
	Lowest	94±4	93±5	<0.001
p- value		<0.001	<0.001	
Patients received supplemental oxygen. Number (%)	On admission	238 (22.9)	399 (40.3)	<0.001
	After admission	315 (30.3)	394(39.8)	<0.001
p- value		<0.001	<0.001	

For statistical analysis first wave was compared with the second wave. Quantitative data were compared using t test (normal data distribution) and Mann Whitney U test for skew data distribution. Qualitative data were compared using Chi-square test.

Table- 3. Showing laboratory parameters and chest X-ray findings

Variables	First wave Mean \pm SD (Median, IQR)	Second wave Mean \pm SD (Median, IQR)	p- value
WBC (10^3 /ul)	6.49 \pm 2.41 (6.10, 4.80-7.60)	6.27 \pm 2.21 (5.90, 4.70-7.40)	0.031
Hemoglobin (g/dl)	14.35 \pm 1.37 (14.40, 13.50- 15.22)	14.16 \pm 1.43 (14.20, 13.3-15.2)	0.003
Platelet count (10^3 /ul)	234.99 \pm 89.44 (217, 175-269)	225.55 \pm 82.50 (209, 168-259)	0.014
Albumin (gm/L)	36.97 \pm 4.83 (37, 34-40)	35.58 \pm 4.94 (35, 32-39)	<0.001
C-Reactive Protein (mg/L)	50.54 \pm 53.28 (35.35, 12.90- 72.02)	33.68 \pm 44.20 (15.2, 15.20- 32.20)	<0.001
Lactate	1.74 \pm 0.77 (1.60, 1.20-2.10)	1.73 \pm 0.91 (1.50, 1.20-2.10)	0.924
Procalcitonin	0.41 \pm 1.62 (0.11, 0.06-0.21)	0.30 \pm 1.15 (0.11, 0.06-0.21)	0.456
D- Dimer	1.20 \pm 4.28 (0.44, 0.32-0.68)	1.10 \pm 3.84 (0.42, 0.30-0.63)	0.139
Aspartate aminotransferase (AST)	44.14 \pm 34.47 (35, 26-50)	50.81 \pm 141.91 (37, 28-52)	0.020
Alkaline phosphatase (ALP)	77.56 \pm 31.71(71, 59-87.5)	78.29 \pm 34.96 (71, 58-87)	0.626
Alanine aminotransferase (ALT)	42.74 \pm 33.28 (32.9, 23-50.55)	44.30 \pm 34.24 (34, 24-54)	0.267
Total Bilurubin	9.97 \pm 5.73 (8.30, 7-12)	9.57 \pm 6.20 (8.0, 6.0-11.0)	0.143
HbA1c	7.37 \pm 2.04 (6.60, 5.90- 8.40)	6.94 \pm 1.83 (6.20, 5.80- 7.3)	<0.001
Chest X ray			

findings			
Unilateral infiltrations	185 (17.8)	236 (23.8)	0.001
Bilateral infiltrations	854 (82.2)	755 (76.2)	

IQR-Interquartile range

Median and IQR were exclusively required for skewed data however to make it unified format we presented it for all the parameters

For statistical analysis first wave was compared with the second wave. Quantitative data were compared using t test (normal data distribution) and Mann Whitney U test for skew data distribution. Qualitative data were compared using Chi-square test.

For peer review only

Table -4. Showing the details of treatment received

Treatment*	First wave (n=1039) n (%)	Second wave (n=991) n(%)	p-value
Dexamethasone	178 (17.1)	473 (47.7)	<0.001
Anticoagulation	1012 (97.4)	981 (99)	0.007
Favipiravir	230 (22.1)	704 (71)	<0.001
Hydroxychloroquine	920(88.5)	598 (60.3)	<0.001
Lopinavir/ ritonavir	369 (35.5)	630 (63.6)	<0.001
Anakinra	28 (2.7)	105 (10.6)	<0.001
Tocilizumab	21 (2.0)	19 (1.9)	0.866
Amoxicillin/clavulanic acid	633 (60.9)	290 (29.3)	<0.001
Ceftriaxone/ Cefuroxime	772 (74.3)	699 (70.5)	0.058
Azithromycin /Clarithromycin	770 (74.1)	415 (41.9) (6.9)	<0.001
Piperacillin /tazobactam	51 (4.9)	68	0.061

*One patient might have received more than one type of treatment

For statistical analysis first wave was compared with the second wave. P-values computed using Pearson Chi-square test.

Table- 5. Showing final outcomes and disposition

Variables	First Wave (n=1030) n (%)	Second wave (n=991) n(%)	p-value
Mechanical ventilation	28 (2.7)	40 (4.0)	0.093
Pulmonary embolism/DVT	3 (0.3)	11 (1.1)	0.025
Death	3 (0.3)	8 (0.8)	0.112
Discharge disposition			
Discharge home	105 (10.1)	222 (22.4)	<0.001
Transfer to quarantine	879 (84.6)	705 (71.1)	
Transfer to higher center	55 (5.3)	64 (6.5)	
Length of stay in days			
Mean \pm SD	14.58 \pm 7.75	12.61 \pm 6.16	<0.001
0-7	227 (21.8)	126 (12.7)	<0.001
8-14	261 (25.1)	638 (64.4)	
15-30	529 (50.9)	212 (21.4)	
>30	22 (2.1)	15 (1.5)	

For statistical analysis first wave was compared with the second wave. Quantitative data were compared using t test for normal data distribution and Mann Whitney U test for skew data distribution. Qualitative data were compared using Chi-square test.

Figure legends

Figure 1.A-C. Box plot showing the distribution of age, duration of symptoms and BMI

Figure 2 A-D. Box plots depicting the vital signs
Figure 2.E-H. Box plots depicting the vital signs

Figure 3. A-F. Box plots depicting distribution laboratory parameters

Figure 3.G-K. Box plots depicting distribution laboratory parameters




Figure 1.A-C.




Figure 2 A-D.




Figure 2 E-H. Boxplots depicting the vital signs




Figure 3 A-F.




Figure 3 G-K.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Check list

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	4-5
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	6-7
Objectives	3	State specific objectives, including any prespecified hypotheses	7
Methods			
Study design	4	Present key elements of study design early in the paper	7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	7
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	NA
Study size	10	Explain how the study size was arrived at	NA
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	

Continued on next page

Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	8-11
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	8-11
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	11
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	8-11
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA
Discussion			
Key results	18	Summarise key results with reference to study objectives	12-16
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	16-17
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12-16
Generalisability	21	Discuss the generalisability (external validity) of the study results	12-16
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	19

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Comparison of demographic, clinical and laboratory characteristics between first and second COVID-19 waves in a secondary care hospital in Qatar: A retrospective study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-061610.R2
Article Type:	Original research
Date Submitted by the Author:	09-Jun-2022
Complete List of Authors:	<p>NAUSHAD, VAMANJORE; Hamad Medical Corporation, Medicine; Qatar University College of Medicine</p> <p>PURAYIL, NISHAN; Hamad Medical Corporation, Medicine; Qatar University College of Medicine</p> <p>CHANDRA, PREM; Hamad Medical Corporation, MEDICAL RESEARCH CENTER</p> <p>Saeed, Abazar Ahmad M; Hamad Medical Corporation, Medicine</p> <p>Radhakrishnan, Pradeep; Hamad Medical Corporation, Medicine</p> <p>VARIKKODAN, IRFAN; Hamad Medical Corporation, Medicine</p> <p>Mathew, Joe V; Hamad Medical Corporation, Medicine; Qatar University College of Medicine</p> <p>Sirajudeen, Jaseem; Hamad Medical Corporation, Medicine; Qatar University College of Medicine</p> <p>Hammamy, Riyadh A; Hamad Medical Corporation, Medicine</p> <p>Badi, Ahmad M; Hamad Medical Corporation, Medicine; Qatar University College of Medicine</p> <p>Suliman, Aasir M; Hamad Medical Corporation, Medicine</p> <p>Badawi, Mohamed N; Hamad Medical Corporation, Department of Infectious Diseases</p> <p>Arya, Saket; Hamad Medical Corporation, Ophthalmology</p> <p>AlMotawa, Maryam; Qatar University College of Medicine</p> <p>Al-Baker, Aisha; Qatar University College of Medicine</p> <p>Alatom, Rania; Qatar University College of Medicine</p> <p>Kartha, Anand; Hamad Medical Corporation, Medicine; Weill Cornell Medicine - Qatar</p>
Primary Subject Heading:	Infectious diseases
Secondary Subject Heading:	Global health
Keywords:	COVID-19, EPIDEMIOLOGY, INFECTIOUS DISEASES

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open: first published as 10.1136/bmjopen-2022-061610 on 28 June 2022. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Title

Comparison of demographic, clinical and laboratory characteristics between first and second COVID-19 waves in a secondary care hospital in Qatar: A retrospective study

Key words

COVID-19 infection, Coronavirus, SARS-CoV-2, Pandemic, First wave, Second wave

For peer review only

Authors and affiliations

Vamanjore A Naushad^{1, 5}

Nishan K Purayil^{1, 5} Email-nishankp@live.com

Prem Chandra² Email-pchandra@hamad.qa

Abazar Ahmad M Saeed¹ Email-asaeed5@hamad.qa

Pradeep Radhakrishnan¹ Email-pradhakrishnan@hamad.qa

Irfan Varikkodan¹ Email-ivarikkodan@hamad.qa

Joe V Mathew^{1, 5} Email-jmathew13@hamad.qa

Jaseem Sirajudeen^{1, 5} Email-jsirajudeen@hamad.qa

Riyadh A Hammamy¹ Email-rhammamy@hamad.qa

Ahmad M Badi^{1, 5} Email-abadi@hamad.qa

Aasir M Suliman¹ Email-asuliman4@hamad.qa

Mohamed N Badawi³ Email-mmohamed21@hamad.qa

Saket Arya⁴ Email-sarya@hamad.qa

Maryam AlMotawa⁵ Email-malmotawa@hamad.qa

Aisha Al-Baker⁵ Email-aalbaker4@hamad.qa

Rania Alatom⁵ Email-Ra1601687@qu.edu.qa

Anand B Kartha^{1, 6} Email-akartha@hamad.qa

1
2
3
4
5
6
7
8
9 1- Department of Medicine

10
11 Hamad Medical Corporation

12
13 2- Medical Research Center

14
15 Hamad Medical Corporation

16
17 3- Department of Infectious Diseases

18
19 Hamad Medical Corporation

20
21 4- Department of Ophthalmology

22
23 Hamad Medical Corporation

24
25 5- College of Medicine- Qatar University

26
27 6-Weill Cornell Medicine-Qatar

28
29
30
31
32
33
34
35
36
37
38 **Corresponding Author**

39
40 V.A.Naushad

41
42 General Internal Medicine Department

43
44 Hamad General Hospital

45
46 Hamad Medical Corporation

47
48 Doha, Qatar

49
50 Email-nousha87@hotmail.com

51
52 Email-vnaushad@hamad.qa

Abstract

Objective: To compare the patient profile and outcomes in Qatar during the first and second waves of the COVID-19 pandemic. **Setting:** A retrospective observational study was conducted comparing the demographic, clinical, and laboratory characteristics of patients with COVID-19 infection admitted to a secondary care hospital, during the first and second waves of the pandemic. **Participants:** 1039 patients from the first wave and 991 from the second wave who had pneumonia on chest X-ray and had a confirmed SARS-CoV-2 infection by a real-time PCR test of a nasopharyngeal swab were included. Patients with a normal chest X-ray and those who had a negative PCR test despite a positive COVID-19 antigen test were excluded. **Outcome:** Length of stay, need for mechanical ventilation, final disposition and mortality were the key outcomes studied **Results:** Flu like symptoms (18.5 % in the first wave vs. 36.1 % in the second wave, $p < 0.001$), cough (79.2% vs.87%, $p < 0.001$) and dyspnea (27.5% vs. 38% $p < 0.001$) were more common in the second wave. Second wave patients had significantly higher respiratory rate, lower peripheral oxygen saturation, needed more supplemental oxygen and had higher incidence of pulmonary embolism. More patients received hydroxychloroquine and antibiotics during the first wave and more received steroids, antivirals and interleukin-1 antagonist during the second wave. The second wave had a shorter length of stay (14.58 ± 7.75 vs. 12.61 ± 6.16), $p < 0.001$) and more patients were discharged home (22% vs. 10% $p < 0.001$). **Conclusions:** Patients who presented during the second wave of Covid-19 pandemic appeared to be more ill clinically and based on their laboratory

1
2
3 parameters.They required shorter hospitalization and were more likely to be
4 discharged home. This could represent greater expertise in handling such patients
5 that was acquired during the first wave as well as use of more appropriate and
6 combination therapies during the second wave.
7
8
9
10
11
12
13
14
15

16 **Strengths**

- 17 ● First study in the region to compare patient characteristics between the two
18 waves
19
- 20 ● All patient variables were compared, including demographics, clinical
21 complaints, vital signs, laboratory indicators, and outcomes.
22
23
24
25
26
27
28

29 **Limitations**

- 30 ● The relationship between risk factors and outcomes was not investigated.
31
32
33
- 34 ● Patients with severe COVID-19 were not included
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Corona virus disease 2019 (COVID-19), first identified in the Wuhan province of China, was declared a global pandemic by the World Health Organization (WHO) on 11 March, 2020 [1]. To date, it has affected 521,920,560 with more than 6 million deaths worldwide. In Qatar, COVID-19 infection has affected 367,099 individuals with 677 deaths till May 2022 [2]. On 29 February 2020 Qatar reported its first confirmed case of COVID-19 infection. During the first and second wave maximum number of cases was reported between 16 April 2020 and 20 July 2020 and between 8 February 2021 and 8 June 2021 respectively.

The virus responsible for the COVID-19 infection is Severe acute respiratory syndrome corona virus (SARS-CoV-2), a novel corona virus belonging to the family Coronaviridae[3].The initial outbreak in China was thought to be originated by zoonotic spread from the seafood markets in the Wuhan province. Afterwards human-to-human transmission was recognized for the community spread of the disease, which rapidly became a global infection leading to the pandemic [4-7].

The mode of transmission of the virus from person to person is via respiratory droplets. Transmission may also occur through fomites such as bed linen, thermometers etc used by the COVID-19 infected patients. Airborne spread has been reported from aerosol generating procedures such as endotracheal intubation, bronchoscopy, open suctioning, tracheostomy, and nebulization [8, 9].

The spectrum of clinical manifestations of COVID-19 infection ranges from asymptomatic infection to symptomatic presentation. A systematic review done before the introduction of the COVID-19 vaccination reported that 33% of COVID -

1
2
3 19 infections are asymptomatic [10]. However these asymptomatic individuals
4
5 can have radiological findings of ground glass opacities or patchy infiltrations in
6
7 CT scan [11] . Most common symptoms of presentations are fever, malaise,
8
9 myalgia, shortness of breath, and dry cough. Gastrointestinal symptoms may also
10
11 be found in some patients with COVID-19 infection [12, 13].
12
13

14
15 The severity of symptomatic disease might vary from mild disease which accounts
16
17 for the majority of the cases to severe or critical illness. Patients with severe
18
19 disease may have dyspnea, hypoxia or radiological imaging demonstrating more
20
21 than 50% involvements of lungs whereas; patients with critical disease will have
22
23 features of shock, respiratory or multi organ failure [14-18]. A report from
24
25 Centers for Disease Control and Prevention (CDC) from United States on
26
27 1.3million cases reported a cumulative incidence of 403.6 cases per 100,000
28
29 persons. The incidence was higher among patients more than 80 years of age.
30
31 Cardiovascular disease (32%) and diabetes mellitus (30%) were the most common
32
33 co-morbid conditions noted. Overall 14% were hospitalized, 2% were admitted to
34
35 the ICU and 5% died. The hospitalization and death were 6 times and 12 times
36
37 respectively higher among patients with underlying co-morbidities than those
38
39 without [19].
40
41
42
43

44 During the first wave the Government of Qatar introduced strict preventive
45
46 measures starting from March 2020, which included closure of all educational
47
48 institutions and commercial establishments, closure of public and private offices,
49
50 restaurants, banning of social gatherings, sports and entertainment activities, ban
51
52 on international travel and strict home confinement. Wearing face mask in public
53
54 space was made mandatory. As the number of cases in the first wave began to
55
56
57
58
59

1
2
3
4 recede, the restrictions were lifted in a phased manner from second half of June
5
6 2020. During the second wave when the number of cases started to raise the
7
8 government reintroduced some of the preventive measures to contain the
9
10 disease starting from February 2021. There was closure of parks, cinemas, sports
11
12 activities. The public and private offices were allowed work with not more than
13
14 50% of capacity and there was ban on social gatherings however there was no
15
16 complete lockdown.
17

18
19 During both pandemic waves, Ras Laffan Hospital, a secondary care hospital, was
20
21 one of the COVID-19 designated hospitals under Hamad Medical Corporation
22
23 (HMC). If patients met the admission criteria, they were transferred to Ras Laffan
24
25 Hospital from non-COVID hospitals and tertiary care COVID facilities. During the
26
27 first and second waves, respectively, 3650 and 4050 patients with a confirmed
28
29 SARS-CoV-2 infection were hospitalized and treated at the Ras Laffan hospital.
30
31

32
33 From the time it was originally discovered in Wuhan, the disease profile,
34
35 epidemiology, and treatment guidelines for COVID-19 infection had evolved
36
37 continuously. On the basis of the most recent scientific findings, WHO released
38
39 and updated diagnostic and treatment guidelines, as well as quarantine
40
41 guidelines, on a regular basis. Countries around the world revised their
42
43 management and quarantine standards on a regular basis based on this and
44
45 locally available data.
46
47

48
49 Although the data on first 5000 cases of COVID-19 infection in Qatar have been
50
51 reported [20], there is a lack of published literature comparing the epidemiology
52
53 and consequences of repeated waves of the COVID-19 pandemic across the
54
55 Middle East area, including Qatar. Furthermore, Qatar's population is made up
56
57
58
59
60

1
2
3 mostly of people of diverse countries and ethnic backgrounds. Hence, we chose to
4 investigate and compare the characteristics and outcomes in both waves to
5
6 better understand and manage future events
7
8
9

10 **Objective**

11
12 The goal of this study was to examine the patient profile and outcomes in COVID-
13
14 19-infected hospitalized patients during the first and second waves of the
15
16 pandemic.
17
18
19

20 **Methods**

21 **Study type and setting**

22
23 A retrospective observational study was conducted at Ras Laffan hospital, Hamad
24
25 Medical Corporation, Qatar. This hospital was one of the COVID-19 designated
26
27 hospitals under HMC.
28
29
30
31
32
33

34 **Study participants and sample selection**

35
36 Patients admitted between 1st to 30th of May 2020 in the first wave (n=1039) and
37
38 those admitted between 1st and 15th of March 2021 during the second wave
39
40 (n=991) were included in the study. The duration of the recruitment of patients
41
42 was shorter in the second wave in order to make it comparable and equal number
43
44 with the first wave. Though we did not use random sampling technique to select
45
46 patients, it is worth to note that all the patients who met the inclusion criteria
47
48 within the specified period were included. The patients were included if they had
49
50 pneumonia on chest X-ray and had a laboratory-confirmed SARS-CoV-2 infection
51
52 by a real-time PCR test of a nasopharyngeal swab specimen. The study excluded
53
54
55
56
57
58
59
60

1
2
3 patients with a normal chest X-ray and those who had a negative PCR test despite
4 a positive COVID-19 antigen test.
5
6
7

8 **Patient and public involvement**

9
10
11 No patient involved
12
13

14 **Data collection**

15
16
17 Using the patients' health care numbers, files from the clinical information system
18 were reviewed. Data was collected on demographics, admission symptoms, co-
19 morbidities, length of stay, laboratory and radiographic results, need for
20 supplemental oxygen, treatment details, complications, and outcomes.
21
22
23
24
25
26

27 **Outcome of the study**

28
29
30 The need for mechanical ventilation, length of stay, final disposition and mortality
31 were the key outcomes studied along with their clinical and laboratory
32 characteristics.
33
34
35
36
37

38 **Statistical analysis**

39
40
41 Descriptive statistics were used to summarize demographic, anthropometric,
42 clinical, laboratory, radiological characteristics, and related follow-up outcome
43 measures of these patients. Continuous variables with normal distribution were
44 presented as mean and standard deviation (SD), whereas median and
45 interquartile range (IQR) was used in case of skewed/non-normal data.
46
47
48 Categorical variables were presented as frequencies and proportions. The
49 Shapiro-Wilk test was used to test for normality of the data distribution. The
50
51
52
53
54
55
56
57
58
59
60

1
2
3 statistical analysis method for outcomes measured quantitatively and differences
4 between the two independent groups (first and second COVID-19 waves) were
5 compared using unpaired t or Mann Whitney U tests as appropriate depending on
6 the normality of the data distribution. Associations between two or more
7 qualitative or categorical variables across two independent groups were
8 compared using Pearson Chi-square or Fisher exact test as applicable. Within each
9 group of COVID-19 wave, vital signs and oxygen requirement measured on and
10 after admission were compared using paired t test and McNemar's Chi-square
11 test. Box plots were constructed to depict distribution of age, duration of
12 symptoms, BMI, vital signs, and various parameters related to laboratory profiles
13 across both groups (first and second COVID-19 waves). All P values presented
14 were two-tailed, and P values <0.05 was considered as statistically significant. All
15 Statistical analyses were performed using statistical packages SPSS version 27.0
16 (Armonk, NY: IBM Corp) and Epi-info (Center for Disease Control and Prevention,
17 Atlanta, GA) software.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

36 Results

37 Baseline demographic characteristics

38
39
40 During the first and second waves, respectively, 3650 and 4050 patients with a
41 confirmed SARS-CoV-2 infection were hospitalized. The study included 1039
42 patients from the first wave and 991 participants from the second wave. During
43 both waves, the average age of the subjects was similar [44.9 ±9.9 vs.
44 44.34±9.56]. In both waves, the proportion of patients among various age groups
45 was comparable, with the majority of patients being between the ages of 36 and
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 50. (52.9 % vs.54.0 %). Males made up 95.2 % of the first wave and 88.5 % of the
4
5
6 second wave patients (Table 1).
7

8 **Clinical characteristics on admission**

9
10
11 In the first wave patients had longer duration of symptoms prior to admission
12 compared to second wave (4.88 ± 2.91 vs. 4.57 ± 2.50 , $p = 0.010$). Flu like symptoms
13 (36.1% in the second wave vs. 18.5% in the first wave, $p < 0.001$), cough (87% vs.
14 79.2%, $p < 0.001$), and shortness of breath (38% vs. 27.5%, $p < 0.001$), were
15 significantly higher in the second wave than the first. We did not find any
16 significant difference in gastrointestinal symptoms between the two waves.
17
18
19

20
21
22 Diabetes mellitus (29.5% vs. 21.9%) and hypertension (26 % vs. 26.5%) were the
23 most common co-morbid conditions observed in both waves; however, frequency
24 of diabetes mellitus was significantly higher in the first wave ($p < 0.001$)
25

26
27
28 The mean body mass index (BMI) was 27.95 ± 4.46 and 28.29 ± 4.83 in the first
29 and second waves, respectively ($p = 0.263$). Most patients had higher BMI in both
30 the waves, with the majority having a BMI between 25.1 to 30 (48.2% vs. 45%)
31 followed by more than 30 (27.1% vs. 28.5%) (Table-1). The details of distribution
32 of age, duration of symptoms and BMI are plotted in Figure 1 A-C.
33
34
35
36
37
38
39
40
41
42
43

44 **Vital signs and oxygen requirement**

45
46
47 Patients in the second wave had significantly higher respiratory rate (23 ± 6 vs.
48 22 ± 5 , $p < 0.001$) and significantly lower peripheral oxygen saturation (93 ± 5 vs.
49 94 ± 4 , $p < 0.001$) when compared to the first wave. Furthermore, during the second
50 wave significantly higher number of patients received supplemental oxygen on
51
52
53
54
55
56
57
58
59
60

admission (40.3% vs. 22.9 %, $p < 0.001$) and also during their stay in the hospital (39.8% vs. 30.3%, $p < 0.001$). During the stay in the hospital there was significant variation in the vital parameters of the patients within the group from admission value to their respective maximum/minimum values ($p < 0.001$) Table- 2 and figure 2 A-H.

Laboratory parameters and chest X-ray findings

The first wave had significantly higher C-reactive protein) (median 35.4, IQR 12.9, 72 vs. median 15.2, IQR 15.2, 32.2, $p < 0.001$ and HbA1c values (7.37 ± 2.04 vs. 6.94 ± 1.83 $p < 0.001$). The mean values of white blood cell count (6.49 ± 2.41 vs. 6.27 ± 2.21 , $p 0.031$), hemoglobin (14.35 ± 1.37 vs. 14.16 ± 1.43 , $p 0.003$), and platelet counts (234.99 ± 89.44 vs. 225.55 ± 82.50 , $p 0.014$) were lower in the second wave than the first. The patients in the second wave, had considerably lower mean albumin levels than the first wave (35.58 ± 4.94 vs. 36.97 ± 4.83 , $p < 0.001$). Patients in the second wave had higher hepatic transaminases and alkaline phosphatase levels than the first wave, although the differences were statistically insignificant. In both waves, the majority of patients had bilateral pneumonia on chest x-ray. Table- 3 and figure 3 A-K.

Treatment received

In the first wave, the usage of amoxicillin/clavulanic acid (60.9% vs.29.3%) and azithromycin/clarithromycin (74.1% vs. 41.9%) and usage of hydroxychloroquine (88.5% vs. 60.3%, $p < 0.001$) was higher.

A significantly higher number of patients in the second wave received steroids (47.7% vs.17.1%, $p < 0.001$), favipiravir (71% vs. 22.1%, $p < 0.001$) or

1
2
3 lopinavir/ritonavir (63.6% vs. 35.5%, $p < 0.001$ and anakinra (10.6% vs. 2.7%, p
4 < 0.001).
5
6

7
8 Similar number of patients in both the waves received cephalosporins (74.3% vs.
9 70.5%, $p = 0.058$) and prophylactic anticoagulation (97.4% vs. 99%). Table - 4.
10
11
12

13 **Complications/ outcome and disposition**

14
15
16
17 In the first and second waves, 5.3% and 6.5 % of patients, respectively, required
18 transfer to a higher center for further care. Among those who were transferred,
19 28 (2.7%) patients in the first wave and 40 (4%) in the second wave received
20 mechanical ventilation ($p = 0.093$). In the second wave, the percentage of patients
21 who developed pulmonary embolism was significantly higher (1.1 % vs. 0.03%,
22 $p = 0.025$), furthermore, a higher proportion of mortality (0.81% (8/991) vs. 0.3%
23 (3/1030)) was recorded in the second wave, however this difference was
24 statistically insignificant ($p = 0.112$).
25
26
27
28
29
30
31
32
33

34
35 In the second wave, the average length of stay was 1.9 days shorter which was
36 statistically significant (14.58 ± 7.75 vs. 12.61 ± 6.16 , $p < 0.001$). The majority of
37 patients in the first wave stayed for 15 to 30 days (50.9 % vs. 21.4%), while the
38 majority of patients in the second wave stayed for 8 to 14 days (64.4% vs.
39 25.15%), table 5.
40
41
42
43
44
45

46
47 There was significantly higher percentage of patients who were transferred to
48 quarantine facility in the first wave than the second wave (84.6% vs. 71.1%,
49 $p < 0.001$) where as significantly higher percentage of patients were discharged to
50 their home in the second wave than the first wave (22.4% vs 10.1%, $p < 0.001$).
51
52
53
54
55
56
57
58
59
60

Discussion

To our knowledge, this is the first study from the state of Qatar to compare COVID-19 individuals hospitalized between the first and second waves of the SARS-CoV-2 pandemic. Our findings show a significant variation between the two waves in terms of clinical features, laboratory markers and outcomes.

There was no difference in the average age of the patients between the two waves. In confirmation to our findings, a previous study conducted in Switzerland by Wolfsburg et al. [21] found no difference in the mean age of patients between two waves (65.9 vs. 65.8 years), whereas in contrast to our results a study by Iftimie et al. from Spain [22] found that the patients in the second wave were significantly younger than the first wave (58 years vs. 67 years). Our research sample, however, was substantially younger in both waves [44.90 9.99 vs. 44.34 9.57] than the previous two study groups. The young male expatriate workforce makes up the bulk of Qatar's population, which might explain this. We predicted the duration of symptoms prior to admission to be longer in the second wave than in the first because the patients were more apprehensive and sought medical assistance earlier in the first wave than in the second. Furthermore, the knowledge acquired and improved understanding of the COVID-19 disease epidemiology gained from handling the first wave should have given health practitioners the confidence to manage patients with mild to moderate disease at home rather than in the hospital during the second wave. Our findings, on the

1
2
3 other hand, revealed that the duration of symptoms before to admission was
4 longer in the first wave than in the second.
5
6
7

8 On admission to the hospital cough, shortness of breath and upper respiratory
9 symptoms were more common in the second wave. The patients in the second
10 wave had more symptoms and were sicker as evidenced by tachypnea and
11 hypoxia and more patients requiring oxygen. We did not observe a significant
12 difference in the prevalence of gastrointestinal symptoms between both the
13 waves. This is in contrast to previous research [22, 23], which reported a higher
14 prevalence of gastrointestinal complaints in the in the second wave.
15
16
17
18
19
20
21
22
23

24 The most common co-morbidities in both waves of the research population were
25 diabetes mellitus and hypertension. The number of diabetes patients, on the
26 other hand, was much higher in the first wave. One possible explanation for the
27 lower number of diabetes mellitus patients in the second wave is that health
28 advice given by the WHO as well as published literature showing evidence of
29 diabetes mellitus as a risk factor for having the severe disease made these
30 patients more cautious and isolate themselves, thereby shielding and protecting
31 them from being exposed to infected patients. When comparing co-morbidities in
32 both the waves, previous research have yielded conflicting outcomes. Iftimie et
33 al. [22] showed no significant differences in co-morbidity between the two waves,
34 however Jarrett et al. [24] and Sargin et al. [25] identified a higher frequency of
35 chronic kidney illness in the second wave than in the first wave.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 Despite the fact that the mean BMI did not alter significantly between the two
52 waves, the majority of our research group had a higher BMI in both, suggesting
53 obesity as a probable risk factor for COVID-19 infection. However this needs
54
55
56
57
58
59
60

1
2
3 further studies analyzing the correlation between obesity as a risk factor and
4 Covid-19 infection. Obesity was found in 30% of the whole study population in
5 both waves, according to a study from Switzerland [21]. Another study from the
6 United States [24] found that the second wave had a higher BMI than the first
7 wave (32.58 vs. 29.83).
8
9

10
11
12
13
14
15 The study of laboratory measurements revealed that the first wave had higher
16 mean values of CRP and HbA1c, while hypoalbuminemia was significantly higher
17 in the second wave. Furthermore levels of leukocyte and platelet count were
18 lower in second wave than the first wave. The second wave had higher mean
19 levels of hepatic transaminases but the difference was statistically not significant.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
The higher HbA1c readings in the first wave are unsurprising given the higher
prevalence of diabetes mellitus in the first wave compared to the second wave.
The higher hepatic transaminases in the second wave could be due to a variety of
factors. One probable reason could be secondary to the side effect of favipiravir,
as it was used more frequently in the second wave than in the first wave.

In our study population, the use of steroids was much higher in the second wave
[47% vs. 17%]. This is because during the early stage of the first wave scientific
literature regarding the benefit of steroids in COVID-19 infection was still in its
preliminary stage and its use was limited. The frequency of usage of steroids in
published data was still greater (99% [24], 76% [21]) than ours in the second
wave. Because the aforementioned two studies included individuals with more
severe disease than our research sample, the frequency of steroid administration
differed. In terms of prophylactic anticoagulation, practically more than 97% of
the patients in both waves received anticoagulation in our research group. This

1
2
3 was much greater than the 59% in the first wave and 74% in the second wave
4 reported in a research conducted in the United States [24].
5
6
7

8 The usage of hydroxychloroquine was significantly higher in the first wave,
9 whereas the use of favipiravir and anakinra was much higher in the second wave,
10 according to our findings. This is because treatment guidelines evolved and
11 modified from the first wave to the second wave based on published scientific
12 information around the world. Furthermore, use of antibiotics was significantly
13 higher in the first wave than the second wave. There are multiple reasons for this.
14 First, during the first wave azithromycin was more commonly used along with
15 hydroxychloroquine as a treatment for COVID-19 infection. Second, due to lack of
16 experience and expertise in managing the COVID-19 pandemic antibiotics were
17 more commonly prescribed for patients with COVID pneumonia during the first
18 wave; however during the second wave clinicians acquired adequate knowledge
19 and experience and were more confident to treat patients without antibiotics
20 unless indicated.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

37 Despite the fact that patients in the second wave were sicker as evidenced by
38 more symptoms, tachypnea and hypoxia on admission and laboratory
39 parameters, the duration of hospitalization were significantly lower in the second
40 wave. In the present study the average length of stay in the second wave was
41 nearly 2 days less than in the first. This supports the findings of other research
42 [21, 22, 25], which similarly found a shorter length of stay in the second wave. In
43 addition more patients were discharged home in the second wave than
44 transferred to quarantine facility. Possible explanation for this could be the
45 change in discharge/transfer criteria. Secondly, better understanding of the
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 disease course and experience of managing the first wave made the health care
4 professionals more confident in early discharge of patients in the second wave.
5
6 Finally, better home surveillance of discharged patients, development of better
7 follow up care, and community awareness and education might have also played
8 an important role.
9
10
11
12
13

14
15 Even while the number of patients who needed to be transferred to a higher
16 center, those who needed mechanical ventilation, had a pulmonary embolism and
17 those who died were all somewhat higher in the second wave than in the first, the
18 difference was not statistically significant. Available published data from two
19 studies, one from Switzerland [21] and another from Turkey [25] found no
20 significant difference in the proportion of patients requiring or at risk for Intensive
21 Care Unit (ICU) admission in both the waves. However, the percentage of patients
22 needing ICU care in the above two studies was higher than our results in both the
23 waves. This could be related to the fact that our study and theirs had different
24 severity of cases and also could be due to the difference in admission criteria in
25 our study and others. Our admission criteria included patients with pneumonia
26 requiring less than 4 L of oxygen at the time of admission, whereas other studies
27 included more severe cases or ICU cases. Others have reported similar results,
28 finding no substantial change in the number of patients requiring mechanical
29 ventilation in both waves [24, 25]. There was no significant change in mortality
30 rates between the two waves in the present study. Previous research comparing
31 mortality rates between the two COVID-19 pandemic waves came up with mixed
32 results. Our findings are consistent with those of Wolfisberg et al.[21] and Sargin
33 et al. [25], who found no difference in mortality rates between the two waves,
34 but Iftimie et al.[22] and Jarrett et al.[24] reported lower mortality in the second
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 wave, in contrast to our findings. Similarly, two studies from the United States
4 found that the second wave had a reduced mortality rate [26, 27]. According to
5 published statistics from Japan based on a public registry reported that the
6 second wave of patients were younger, had fewer underlying co-morbidities, and
7 had lower mortality rates [28].
8
9

10
11
12 A few studies from Europe also found lower mortality in the second wave. Chest
13 X-ray severity of pneumonia, in-hospital mortality, and CRP readings were
14 considerably greater in the first wave, according to an Italian study involving 200
15 Caucasian males over 50 years. They also discovered that the first wave had more
16 patients who required mechanical ventilation [29]. Another study from Spain
17 found that the second wave had younger patients, a shorter duration of stay in
18 the hospital, fewer invasive mechanical ventilation, and decreased mortality [22].
19
20

21
22 The first wave's experience and lessons acquired by health care professionals, as
23 well as a collaborative team effort involving numerous government agencies and
24 community awareness and engagement, have helped us to manage the second
25 wave more effectively.
26
27

28 29 30 31 32 33 34 35 36 37 38 39 40 41 **Limitations**

42
43 There were certain limitations to our research. To begin with, some data on co-
44 morbidity and symptoms may have been overlooked due to the retrospective
45 nature of the study. Second, there might have been selection bias because our
46 research population was mostly male patients as most female COVID-19 patients
47 were admitted to other COVID designated hospitals. Third, because our research
48 sample included only mild to moderate Covid-19 infections, the findings may not
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 be generalized to severe COVID -19 infections. Finally, the relationship between
4 risk variables and outcomes was not examined as it was not the primary goal of
5 our study.
6
7
8
9

10 **Recommendation for future research**

11
12
13
14 Future study should compare the relationship between various risk variables and
15 outcomes over serial COVID-19 waves. Long-term consequences of COVID-19
16 infection in the first and second waves can also be studied and compared.
17
18
19
20

21 **Conclusions**

22
23
24 Patients in the second wave were more symptomatic and unwell than those in the
25 first wave, but they stayed in the hospital for a shorter time and were more likely
26 to be discharged home, according to our data. The most prevalent symptoms in
27 both waves were cough and shortness of breath, although they were much
28 greater in the second wave. Diabetes mellitus and raised CRP levels were more
29 common in the first wave, but hypoalbuminemia was more prevalent in the
30 second wave. In the first wave, antibiotics and hydroxychloroquine were more
31 commonly utilized, but in the second wave, steroids, antivirals, and interleukin-1
32 antagonists were more commonly employed. There was no significant difference
33 in the need for mechanical ventilation or mortality rate between the two waves.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Author's contribution

VN- Study design, data collection, analysis, manuscript writing, editing

NP- Study design, data collection, analysis, manuscript writing, editing

PC- Study design, data analysis, editing

AS- Data collection, analysis

PR- Data collection, analysis

IV- Study design, editing

JM- Analysis, manuscript writing

JS- Data collection, literature review

RH- Data collection, manuscript writing

AB- Data collection, manuscript writing

AA- Data collection, editing

MB- Data analysis, manuscript writing

SA- Data collection, manuscript writing

MA- Data collection, editing

AA- Data collection, literature review

RA- Data collection, literature review

AK- Data analysis, manuscript writing, editing

Acknowledgement

Nil

Competing interests' statement

The authors declare that they have no competing interest involved

Funding

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors

Data sharing statement

No additional data available

Ethical approval

The study was approved by the Institutional Review Board and Medical Research Center-institutional research committee of Hamad Medical Corporation (Approval # MRC-01-21-312).

References

1. <https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19>
2. <https://covid19.moph.gov.ga/EN/Pages/default.aspx>
3. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: a review [published online ahead of print, 2020 Apr 20]. *Clin Immunol*. 2020; 215:108427)
4. Parasher A. COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. *Postgrad Med J*. 2021 May;97(1147):312-320. doi: 10.1136/postgradmedj-2020-138577. Epub 2020 Sep 25. PMID: 32978337.
5. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. *N Engl J Med* 2020;382:1199–207.
6. Zheng M, Gao Y, Wang G, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. *Cell Mol Immunol* 2020.
7. Zhang J, Litvinova M, Wang W, et al. Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study. *Lancet Infect Dis* 2020;20:793–802.)
8. Burke RM, Midgley CM, Dratch A, et al. Active monitoring of persons exposed to patients with confirmed COVID-19: United States, January–February 2020. *MMWR Morb Mortal Wkly Rep* 2020
9. Ong SW, Tan YK, Chia PY, et al. Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient. *JAMA* 2020;323:1610).

- 1
2
3 10.Oran DP, Topol EJ. The Proportion of SARS-CoV-2 Infections That Are Asymptomatic : A
4 Systematic Review. *Ann Intern Med.* 2021 May;174(5):655-662. doi: 10.7326/M20-6976. Epub
5 2021 Jan 22. PMID: 33481642; PMCID: PMC7839426
6
7
8
9
10 11. Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, Ma H, Chen W, Lin Y, Zheng Y, Wang J, Hu Z, Yi Y,
11 Shen H. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among
12 close contacts in Nanjing, China. *Sci China Life Sci.* 2020 May;63(5):706-711. doi:
13 10.1007/s11427-020-1661-4. Epub 2020 Mar 4. PMID: 32146694; PMCID: PMC7088568
14
15
16
17
18 12. Cheung KS, Hung IF, Chan PP, et al. Gastrointestinal manifestations of SARS-CoV-2 infection
19 and virus load in fecal samples from the hong kong cohort and systematic review and meta-
20 analysis. *Gastroenterology* 2020;
21
22
23
24 13. Available <https://www.webmd.com/lung/COVID19-digestive-symptoms> .
25
26
27
28 14.Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J,
29 Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q,
30 Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan,
31 China. *Lancet.* 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub
32 2020 Jan 24. Erratum in: *Lancet.* 2020 Jan 30;; PMID: 31986264; PMCID: PMC7159299.
33
34
35
36
37 15.Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang
38 X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus
39 pneumonia in Wuhan, China: a descriptive study. *Lancet.* 2020 Feb 15;395(10223):507-513. doi:
40 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30. PMID: 32007143; PMCID: PMC7135076.
41
42
43
44
45
46 16.Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y,
47 Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel
48 Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA.* 2020 Mar 17;323(11):1061-1069. doi:
49 10.1001/jama.2020.1585. Erratum in: *JAMA.* 2021 Mar 16;325(11):1113. PMID: 32031570;
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 17. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y, Pan S, Zou
4 X, Yuan S, Shang Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2
5 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet*
6
7 *Respir Med*. 2020 May;8(5):475-481. doi: 10.1016/S2213-2600(20)30079-5. Epub 2020 Feb 24.
8
9 Erratum in: *Lancet Respir Med*. 2020 Apr;8(4):e26. PMID: 32105632; PMCID: PMC7102538.
10
11
12
13 18. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus
14 Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the
15 Chinese Center for Disease Control and Prevention. *JAMA*. 2020 Apr 7;323(13):1239-1242. doi:
16
17 10.1001/jama.2020.2648. PMID: 32091533. 020).
18
19
20
21 19. Stokes EK, Zambrano LD, Anderson KN, Marder EP, Raz KM, El Burai Felix S, Tie Y, Fullerton
22 KE. Coronavirus Disease 2019 Case Surveillance - United States, January 22-May 30, 2020.
23
24 *MMWR Morb Mortal Wkly Rep*. 2020 Jun 19;69(24):759-765. doi: 10.15585/mmwr.mm6924e2.
25
26 PMID: 32555134; PMCID: PMC7302472.
27
28
29
30 20. Omrani AS, Almaslamani MA, Daghfal J, Alattar RA, Elgara M, Shaar SH, Ibrahim TBH, Zaout
31 A, Bakdach D, Akkari AM, Baiou A, Alhariri B, Elajez R, Husain AAM, Badawi MN, Abid FB, Abu
32 Jarir SH, Abdalla S, Kaleeckal A, Choda K, Chinta VR, Sherbash MA, Al-Ismaïl K, Abukhattab M,
33 Ait Hssain A, Coyle PV, Bertollini R, Frenneaux MP, Alkhal A, Al-Kuwari HM. The first consecutive
34 5000 patients with Coronavirus Disease 2019 from Qatar; a nation-wide cohort study. *BMC*
35
36 *Infect Dis*. 2020 Oct 19;20(1):777. doi: 10.1186/s12879-020-05511-8. PMID: 33076848; PMCID:
37
38 PMC7570422.
39
40
41
42
43 21. Wolfisberg S, Gregoriano C, Struja T, et al. Comparison of characteristics, predictors and
44 outcomes between the first and second COVID-19 waves in a tertiary care centre in
45 Switzerland: an observational analysis. *Swiss Med Wkly*. 2021;151:w20569. Published 2021 Aug
46
47 10. doi:10.4414/smw.2021.20569
48
49
50 22. Iftimie S, López-Azcona AF, Vallverdú I, et al. First and second waves of coronavirus disease-
51 19: A comparative study in hospitalized patients in Reus, Spain. *PLoS One*.
52 2021;16(3):e0248029. Published 2021 Mar 31. doi:10.1371/journal.pone.0248029
53
54
55
56
57
58
59

- 1
2
3 23. Jalali SF, Ghassemzadeh M, Mouodi S, et al. Epidemiologic comparison of the first and
4 second waves of coronavirus disease in Babol, North of Iran. *Caspian J Intern Med*.
5 2020;11(Suppl 1):544-550. doi:10.22088/cjim.11.0.544
6
7
8 24. Jarrett SA, Lo KB, Shah S, et al. Comparison of Patient Clinical characteristics and Outcomes
9 Between Different COVID-19 Peak Periods: A Single Center Retrospective Propensity Matched
10 Analysis. *Cureus*. 2021;13(6):e15777. Published 2021 Jun 20. doi:10.7759/cureus.15777
11
12
13 25. Sargin Altunok E, Satici C, Dinc V, et al. Comparison of demographic and clinical
14 characteristics of hospitalized COVID-19 patients with severe/critical illness in the first wave
15 versus the second wave. *J Med Virol*. 2022;94(1):291-297. doi:10.1002/jmv.27319
16
17
18 26. Vahidy FS, Drews AL, Masud FN, et al. Characteristics and Outcomes of COVID-19 Patients
19 During Initial Peak and Resurgence in the Houston Metropolitan Area. *JAMA*. 2020;324(10):998-
20 1000. doi:10.1001/jama.2020.15301
21
22
23 27. Hoogenboom WS, Pham A, Anand H, et al. Clinical characteristics of the first and second
24 COVID-19 waves in the Bronx, New York: A retrospective cohort study. *Lancet Reg Health Am*.
25 2021;3:100041. doi:10.1016/j.lana.2021.100041
26
27
28 28. Saito S, Asai Y, Matsunaga N, et al. First and second COVID-19 waves in Japan: A comparison
29 of disease severity and characteristics. *J Infect*. 2021;82(4):84-123.
30 doi:10.1016/j.jinf.2020.10.033
31
32
33 29. Borghesi A, Golemi S, Carapella N, Zigliani A, Farina D, Maroldi R. Lombardy, Northern Italy:
34 COVID-19 second wave less severe and deadly than the first? A preliminary investigation. *Infect*
35 *Dis (Lond)*. 2021;53(5):370-375. doi:10.1080/23744235.2021.1884745
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table-1. Baseline epidemiological and clinical characteristics of patients during the first and second wave of the COVID – 19 pandemic

Variables	First wave (n=1039) n (%)	Second wave (n=991) n (%)	p- value
Age (in years)			
Mean \pm SD	44.90 \pm 9.99	44.34 \pm 9.57	0.194**
18 - 35	202 (19.4)	192 (19.4)	0.896*
36 - 50	550 (52.9)	535 (54)	
51 -65	265 (25.5)	247 (24.9)	
Above 65	22 (2.1)	17 (1.7)	
Gender			
Male	989 (95.2)	877 (88.5)	<0.001*
Female	50 (4.8)	114 (11.5)	
Signs and symptoms			
Asymptomatic	48 (4.6)	94 (9.5)	<0.001*
Mean duration of symptoms in days \pm SD	4.88 \pm 2.91	4.57 \pm 2.50	0.010**
Fever	893 (85.9)	870 (87.8)	0.220*
Respiratory symptoms	856 (82.4)	709 (71.5)	<0.001*
Flu like symptoms	192 (18.5)	358 (36.1)	<0.001*
Cough	823 (79.2)	862 (87)	<0.001*
Shortness of breath	286 (27.5)	377 (38)	<0.001*
Chest pain	43(4.1)	37(3.7)	0.639*
GI symptoms	88 (8.5)	66 (6.7)	0.124*
Vomiting	50 (4.8)	38 (3.8)	0.280*
Diarrhea	49 (4.7)	38 (3.8)	0.327*
Co-Morbidities			

Immunosuppression	12 (1.2)	4 (0.4)	0.056*
Chemotherapy	6 (0.6)	5 (0.5)	0.823*
Diabetes Mellitus	307(29.5)	217 (21.9)	<0.001*
Hypertension	270 (26)	263 (26.5)	0.777*
Coronary artery disease	41 (3.9)	26 (2.6)	0.095*
Chronic kidney disease	17 (1.6)	14 (1.4)	0.681*
Cancer	5 (0.5)	5 (0.5)	0.940*
Liver disease	3 (0.3)	6 (0.6)	0.283*
COPD/Asthma	19 (1.8)	8 (0.8)	0.045*
Body mass index (kg/m²)			
Mean ± SD	27.95 ±4.46	28.29 ± 4.83	0.263**
< 18.5	1(0.2)	6 (1.1)	0.360*
18.6 – 25	102 (24.5)	137 (25.4)	
25.1– 30	201 (48.2)	243 (45)	
>30	113 (27.1)	154 (28.5)	

*Pearson Chi-square test. **Unpaired t test.

Categorical and quantitative data expressed as frequencies and percentages (in parenthesis) and as mean ± SD.

In all statistical comparative analysis performed, second wave was considered as a reference group.

COPD: Chronic obstructive pulmonary disease

Table-2. Showing vital Signs and oxygen requirement

Variables		First wave (n=1039)	Second wave (n=991)	p- value*
Temperature °C Mean ±SD	On admission	37.3±0.75	37.3± 0.72	0.976
	Maximum	38.1±0.89	38.2±0.88	0.024
p-value**		<0.001	<0.001	
Pulse rate (Beats per minute) Mean ±SD	On admission	89±14	88±13	0.439
	Maximum	102±11	103±11	0.164
p- value**		<0.001	<0.001	
Respiratory Rate /min Mean ±SD	On admission	19±2	19±3	0.030
	Maximum	22±5	23±6	<0.001
p- value**		<0.001	<0.001	
Spo2 (%) Mean ±SD	On admission	97±2	97±1	0.327
	Lowest	94±4	93±5	<0.001
p- value**		<0.001	<0.001	
Patients received supplemental oxygen, number (%)	On admission	238 (22.9)	399 (40.3)	<0.001
	After admission	315 (30.3)	394(39.8)	<0.001
p- value***		<0.001	<0.001	

*Unpaired t test. **Paired t test. *** McNemar's Chi-Square test

In all statistical comparative analysis performed, second wave was considered as a reference group.

Table- 3. Showing laboratory parameters and chest X-ray findings

Variables	First wave Mean \pm SD (Median, IQR)	Second wave Mean \pm SD (Median, IQR)	p- value
WBC (10^3 /ul)	6.49 \pm 2.41 (6.10, 4.80-7.60)	6.27 \pm 2.21 (5.90, 4.70-7.40)	0.031*
Hemoglobin (g/dl)	14.35 \pm 1.37 (14.40, 13.50- 15.22)	14.16 \pm 1.43 (14.20, 13.3-15.2)	0.003*
Platelet count (10^3 /ul)	234.99 \pm 89.44 (217, 175-269)	225.55 \pm 82.50 (209, 168-259)	0.014*
Albumin (gm/L)	36.97 \pm 4.83 (37, 34-40)	35.58 \pm 4.94 (35, 32-39)	<0.001*
C-Reactive Protein (mg/L)	50.54 \pm 53.28 (35.35, 12.90- 72.02)	33.68 \pm 44.20 (15.2, 15.20- 32.20)	<0.001**
Lactate	1.74 \pm 0.77 (1.60, 1.20-2.10)	1.73 \pm 0.91 (1.50, 1.20-2.10)	0.924*
Procalcitonin	0.41 \pm 1.62 (0.11, 0.06-0.21)	0.30 \pm 1.15 (0.11, 0.06-0.21)	0.456**
D- Dimer	1.20 \pm 4.28 (0.44, 0.32-0.68)	1.10 \pm 3.84 (0.42, 0.30-0.63)	0.139**
Aspartate aminotransferase (AST)	44.14 \pm 34.47 (35, 26-50)	46.81 \pm 40.14 (37, 28-52)	0.020**
Alkaline phosphatase (ALP)	77.56 \pm 31.71(71, 59-87.5)	78.29 \pm 34.96 (71, 58-87)	0.626*
Alanine aminotransferase (ALT)	42.74 \pm 33.28 (32.9, 23-50.55)	44.30 \pm 34.24 (34, 24-54)	0.267**
Total Bilurubin	9.97 \pm 5.73 (8.30, 7-12)	9.57 \pm 6.20 (8.0, 6.0-11.0)	0.143*
HbA1c	7.37 \pm 2.04 (6.60, 5.90- 8.40)	6.94 \pm 1.83 (6.20, 5.80- 7.3)	<0.001*
Chest X ray findings			
Unilateral	185 (17.8)	236 (23.8)	0.001***

infiltrations			
Bilateral infiltrations	854 (82.2)	755 (76.2)	

*Unpaired t test. **Mann Whitney U test. ***Pearson Chi-Square test

IQR-Interquartile range

In all statistical comparative analysis performed, second wave was considered as a reference group.

For peer review only

Table -4. Showing the details of treatment received

Treatment†	First wave (n=1039) n (%)	Second wave (n=991) n (%)	p-value*
Dexamethasone	178 (17.1)	473 (47.7)	<0.001
Anticoagulation	1012 (97.4)	981 (99)	0.007
Favipiravir	230 (22.1)	704 (71)	<0.001
Hydroxychloroquine	920(88.5)	598 (60.3)	<0.001
Lopinavir/ ritonavir	369 (35.5)	630 (63.6)	<0.001
Anakinra	28 (2.7)	105 (10.6)	<0.001
Tocilizumab	21 (2.0)	19 (1.9)	0.866
Amoxicillin/clavulanic acid	633 (60.9)	290 (29.3)	<0.001
Ceftriaxone/ Cefuroxime	772 (74.3)	699 (70.5)	0.058
Azithromycin /Clarithromycin	770 (74.1)	415 (41.9)	<0.001
Piperacillin /tazobactam	51 (4.9)	68 (6.9)	0.061

*Pearson Chi-square test.

In all statistical comparative analysis performed, second wave was considered as a reference group.

†Some patients might have received more than one type of treatments.

Table- 5. Showing final outcomes and disposition

Variables	First Wave (n=1030) n (%)	Second wave (n=991) n(%)	p-value
Mechanical ventilation	28 (2.7)	40 (4.0)	0.093*
Pulmonary embolism/DVT	3 (0.3)	11 (1.1)	0.025*
Death	3 (0.3)	8 (0.8)	0.112*
Discharge disposition			
Discharge home	105 (10.1)	222 (22.4)	<0.001*
Transfer to quarantine	879 (84.6)	705 (71.1)	
Transfer to higher center	55 (5.3)	64 (6.5)	
Length of stay in days			
Mean \pm SD	14.58 \pm 7.75	12.61 \pm 6.16	<0.001 **
0-7	227 (21.8)	126 (12.7)	<0.001*
8-14	261 (25.1)	638 (64.4)	
15-30	529 (50.9)	212 (21.4)	
>30	22 (2.1)	15 (1.5)	

*Pearson Chi-Square test. **Unpaired t test.

In all statistical comparative analysis performed, second wave was considered as a reference group.

Figure legends

Figure 1.A-C. Box plot showing the distribution of age, duration of symptoms and BMI

Figure 2 A-D. Box plots depicting the vital signs

Figure 2.E-H. Box plots depicting the vital signs

Figure 3. A-F. Box plots depicting distribution laboratory parameters

Figure 3.G-K. Box plots depicting distribution laboratory parameters




Figure 1.A-C.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2 A-D.

review only




Figure 2 E-H. Boxplots depicting the vital signs

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3 A-F.




Figure 3 G-K.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Check list

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	4-5
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	6-7
Objectives	3	State specific objectives, including any prespecified hypotheses	7
Methods			
Study design	4	Present key elements of study design early in the paper	7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	7
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	NA
Study size	10	Explain how the study size was arrived at	NA
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	

Continued on next page

Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	8-11
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	8-11
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	11
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	8-11
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA
Discussion			
Key results	18	Summarise key results with reference to study objectives	12-16
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	16-17
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12-16
Generalisability	21	Discuss the generalisability (external validity) of the study results	12-16
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	19

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.